Venous thromboembolism (VTE) in Europe

Thrombosis and Haemostasis 98, 756-764 DOI: 10.1160/th07-03-0212

Citation Report

#	Article	IF	CITATIONS
1	February 11, 1964. Clin-Alert, 1964, 2, 11-13.	0.3	1
2	Effect of the increasing use of coronary angioplasty on outcome at one year in patients with unstable angina Heart, 1995, 74, 680-684.	1.2	2
3	Oral Factor Xa Inhibitors for Venous Thromboembolism Prevention in Major Orthopedic Surgery: A Review. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2007, 36, 217-226.	0.5	3
4	Determinants of healthâ€related quality of life during the 2 years following deep vein thrombosis. Journal of Thrombosis and Haemostasis, 2008, 6, 1105-1112.	1.9	415
5	Clinical predictors of prophylaxis use prior to the onset of acute venous thromboembolism in hospitalized patients SWIss Venous ThromboEmbolism Registry (SWIVTER). Journal of Thrombosis and Haemostasis, 2008, 6, 2082-2087.	1.9	44
8	Trombofilia. Medicine, 2008, 10, 1475-1482.	0.0	0
9	Prevention of in-hospital VTE: why can't we do better?. Lancet, The, 2008, 371, 361-362.	6.3	36
10	Increasing the platelet count in chronic ITP. Lancet, The, 2008, 371, 362-364.	6.3	4
11	Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet, The, 2008, 371, 387-394.	6.3	1,258
12	New diagnostic strategies for pulmonary embolism. Lancet, The, 2008, 371, 1312-1315.	6.3	13
14	Globaltest versus Profil: Wird das endogene Thrombinpotential das etablierte Thrombophiliescreening ablösen? Pro. / Global coagulation assays versus differentiated testing: will endogenous thrombin potential replace established thrombophilia screening? Pro Laboratoriums Medizin, 2008, 32, 193-196.	0.1	0
15	Global coagulation assays versus differentiated testing: will endogenous thrombin potential replace established thrombophilia screening? Pro. 1. Laboratoriums Medizin, 2008, 32,	0.1	Ο
16	Prevention and treatment of venous thromboembolism in older people. Reviews in Clinical Gerontology, 2008, 18, 219-228.	0.5	3
17	Awareness and Politics of Venous Thromboembolism in the United Kingdom. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 398-399.	1.1	18
18	Effect of fondaparinux 2.5 mg once daily on mortality: a meta-analysis of phase III randomized trials of venous thromboembolism prevention. Country Review Ukraine, 2008, 10, C8-C13.	0.8	12
19	Are isolated distal deep-vein thromboses clinically significant?. Therapy: Open Access in Clinical Medicine, 2008, 5, 151-157.	0.2	7
21	Constriction of carotid arteries by urokinase-type plasminogen activator requires catalytic activity and is independent of NH2-terminal domains. Thrombosis and Haemostasis, 2009, 102, 983-992.	1.8	3
22	Venous thromboembolism: a UK perspective. British Journal of Hospital Medicine (London, England:) Tj ETQq1 1	0.784314	rgBT /Overlo

#	Article	IF	CITATIONS
23	In-hospital symptomatic venous thromboembolism and antithrombotic prophylaxis in Internal Medicine. Thrombosis and Haemostasis, 2009, 101, 893-901.	1.8	38
24	Lack of extended venous thromboembolism prophylaxis in high-risk patients undergoing major orthopaedic or major cancer surgery. Thrombosis and Haemostasis, 2009, 102, 56-61.	1.8	41
25	Mechanical Prevention of Venous Thromboembolism. , 0, , 421-434.		0
26	Venous thromboembolic events in hospitalised medical patients. Thrombosis and Haemostasis, 2009, 102, 505-510.	1.8	57
27	Implications of Thromboprophylaxis Registry Data on Clinical Practice. American Journal of the Medical Sciences, 2009, 338, 58-63.	0.4	3
28	Association of fatigue and psychological distress with quality of life in patients with a previous venous thromboembolic event. Thrombosis and Haemostasis, 2009, 102, 1219-1226.	1.8	36
29	The role of monocytes in thrombotic disorders. Thrombosis and Haemostasis, 2009, 102, 916-924.	1.8	123
30	Association of influenza vaccination with reduced risk of venous thromboembolism. Thrombosis and Haemostasis, 2009, 102, 1259-1264.	1.8	32
31	Update on acute pulmonary embolism. European Respiratory Review, 2009, 18, 137-147.	3.0	21
32	The CMS Ruling on Venous Thromboembolism After Total Knee or Hip Arthroplasty. JAMA - Journal of the American Medical Association, 2009, 301, 1063.	3.8	75
33	Venous Thromboembolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 298-310.	1.1	179
34	PREVENTION AND TREATMENT OF THROMBOEMBOLIC EVENTS IN MEDICAL PATIENTS AND NEW ANTICOAGULANTS. Acta Clinica Belgica, 2009, 64, 547-552.	0.5	1
35	Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials. Expert Review of Cardiovascular Therapy, 2009, 7, 569-576.	0.6	14
36	Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. Journal of Bone and Joint Surgery: British Volume, 2009, 91-B, 636-644.	3.4	152
37	State-of-the-Art Review: Assessing the Safety Profiles of New Anticoagulants for Major Orthopedic Surgery Thromboprophylaxis. Clinical and Applied Thrombosis/Hemostasis, 2009, 15, 377-388.	0.7	43
39	Risk stratification for venous thromboembolism in hospitalized patients in a developing country: a prospective study. Journal of Thrombosis and Thrombolysis, 2009, 28, 309-313.	1.0	18
40	Venous thromboembolism in abdominal cancer surgery. Clinical Journal of Gastroenterology, 2009, 2, 247-251.	0.4	4
42	The prevention of hospitalâ€acquired venous thromboembolism in the United Kingdom. British Journal of Haematology, 2009, 144, 642-652.	1.2	34

#	Article	IF	CITATIONS
43	Physician compliance with advanced electronic alerts for preventing venous thromboembolism among hospitalized medical patients. Journal of Thrombosis and Haemostasis, 2009, 7, 1291-1296.	1.9	44
44	Prophylaxis of venous thromboembolism in the US: improving hospital performance. Journal of Thrombosis and Haemostasis, 2009, 7, 1437-1445.	1.9	22
45	Histological age determination of venous thrombosis: A neglected forensic task in fatal pulmonary thrombo-embolism. Forensic Science International, 2009, 186, 22-28.	1.3	98
49	Low-Molecular-Weight Heparin Prophylaxis of Deep Vein Thrombosis for Older Patients with Restricted Mobility. Drugs and Aging, 2009, 26, 263-271.	1.3	4
50	Recent developments in the use of oral anticoagulants. Expert Opinion on Pharmacotherapy, 2009, 10, 1769-1781.	0.9	8
51	The need for new oral anticoagulants in clinical practice. Journal of Cardiovascular Medicine, 2009, 10, 605-609.	0.6	15
52	Low-molecular-weight heparin for thromboprophylaxis. Current Opinion in Pulmonary Medicine, 2009, 15, 443-454.	1.2	6
53	F9 Malmo, factor IX and deep vein thrombosis. Haematologica, 2009, 94, 693-699.	1.7	27
54	New Anticoagulants: Focus on Venous Thromboembolism. Current Vascular Pharmacology, 2009, 7, 309-329.	0.8	26
55	Venous Imaging. Methodist DeBakey Cardiovascular Journal, 2009, 5, 7-13.	0.5	0
56	Risk assessment as a guide to thrombosis prophylaxis. Current Opinion in Pulmonary Medicine, 2010, 16, 448-452.	1.2	122
57	Reducing the risk of VTE: the new NICE clinical guideline. NursePrescribing, 2010, 8, 589-594.	0.1	1
58	Evaluation of the diagnostic yield of D-dimer testing in suspected venous thromboembolism in primary care: a 2-year retrospective analysis. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2010, 20, 102-103.	2.5	3
59	Asia-Pacific Thrombosis Advisory Board consensus paper on prevention of venous thromboembolism after major orthopaedic surgery. Thrombosis and Haemostasis, 2010, 104, 919-930.	1.8	30
60	Clinical and genetic risk factors for venous thromboembolism in Chinese population. Frontiers of Medicine in China, 2010, 4, 29-35.	0.1	2
61	Development of national performance measures on the prevention and treatment of venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2010, 29, 148-154.	1.0	11
62	Unprovoked Venous Thromboembolism: Short term or Indefinite Anticoagulation? Balancing Long-Term Risk and Benefit. Blood Reviews, 2010, 24, 171-178.	2.8	34
63	A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. Journal of Thrombosis and Haemostasis, 2010, 8, 2450-2457.	1.9	864

#	Article	IF	CITATIONS
64	Defining the population in need of thromboprophylaxis – making hospitals safer. British Journal of Haematology, 2010, 149, 805-812.	1.2	8
65	Thrombolysis for pulmonary embolism: Past, present and future. Thrombosis and Haemostasis, 2010, 103, 877-883.	1.8	30
66	NICE and venous thromboembolism. Journal of Bone and Joint Surgery: British Volume, 2010, 92-B, 609-610.	3.4	19
67	Risk Factors for Nonfatal Pulmonary Embolism in a Japanese Population: A Hospital-Based Case-control Study. Angiology, 2010, 61, 269-274.	0.8	14
68	Developing guidelines for venous thromboembolism for The National Institute for Clinical Excellence. Journal of Bone and Joint Surgery: British Volume, 2010, 92-B, 611-616.	3.4	20
69	Video meliora proboque sed deteriora sequor: the case of thromboprophylaxis in hospitalized cancer patients. Annals of Oncology, 2010, 21, 911-913.	0.6	2
70	Indications for Catheter-Directed Thrombolysis in the Management of Acute Proximal Deep Venous Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 669-674.	1.1	79
72	Clinical burden of venous thromboembolism. Current Medical Research and Opinion, 2010, 26, 2465-2473.	0.9	38
73	Raman Spectroscopy As A Potential Rapid Screening Tool For Venous Thromboembolism. , 2010, , .		0
75	Pulmonary Thromboembolic Disease. Clinical Management of Acute and Chronic Disease. Revista Espanola De Cardiologia (English Ed), 2010, 63, 832-849.	0.4	5
76	Diagnostic algorithm for thrombophilia screening. Clinical Chemistry and Laboratory Medicine, 2010, 48, S27-39.	1.4	11
77	ICD-10 hospital discharge diagnosis codes were sensitive for identifying pulmonary embolism but not deep vein thrombosis. Journal of Clinical Epidemiology, 2010, 63, 790-797.	2.4	57
78	Prevalence and Clinical History of Incidental, Asymptomatic Pulmonary Embolism: A Meta-Analysis. Thrombosis Research, 2010, 125, 518-522.	0.8	189
79	Venous thromboembolism (VTE) in cancer patients. ESMO Clinical Recommendations for prevention and management. Thrombosis Research, 2010, 125, S117-S119.	0.8	39
80	Enfermedad tromboembólica pulmonar. Manejo clÃnico de la enfermedad aguda y crónica. Revista Espanola De Cardiologia, 2010, 63, 832-849.	0.6	17
81	Venöse Thromboembolien. , 2010, , 391-460.		0
82	Overview of Venous Thromboembolism. Drugs, 2010, 70, 3-10.	4.9	55
84	Predicting venous thromboembolism in hospitalized medical patients: are we there yet?. Expert Review of Hematology, 2011, 4, 1-3.	1.0	3

#	Article	IF	CITATIONS
86	Mortality Risk Assessment and the Role of Thrombolysis in Pulmonary Embolism. Critical Care Clinics, 2011, 27, 953-967.	1.0	22
87	A cross-sectional evaluation of venous thromboembolism risk and use of venous thromboembolism prophylaxis in hospitalized patients in Senegal. Archives of Cardiovascular Diseases, 2011, 104, 493-501.	0.7	18
88	Natural anticoagulants and thrombophilia. , 2011, , 583-595.		3
89	Clinical Review of Pulmonary Embolism: Diagnosis, Prognosis, and Treatment. Medical Clinics of North America, 2011, 95, 1203-1222.	1.1	19
90	Thromboprophylaxis: medical recommendations and hospital programs. Revista Da Associação Médica Brasileira (English Edition), 2011, 57, 87-97.	0.1	4
91	Systematic Review of the Use of Retrievable Inferior Vena Cava Filters. Journal of Vascular and Interventional Radiology, 2011, 22, 1522-1530.e3.	0.2	398
92	Emerging options in the treatment of deep vein thrombosis and pulmonary embolism. Blood Reviews, 2011, 25, 215-221.	2.8	20
94	The mechanism of action of rivaroxaban – an oral, direct Factor Xa inhibitor – compared with other anticoagulants. Thrombosis Research, 2011, 127, 497-504.	0.8	117
95	Outpatient management of acute deep vein thrombosis: Results from the OTIS-DVT registry. Thrombosis Research, 2011, 127, 406-410.	0.8	16
96	Effectiveness and safety of thromboprophylaxis with enoxaparin in medical inpatients. Thrombosis Research, 2011, 128, 440-445.	0.8	11
97	MP's and VTE's: Fact or fiction. Thrombosis Research, 2011, 128, 505-506.	0.8	5
98	Patent Foramen Ovale and Major Pulmonary Embolism. Journal of Cardiothoracic and Vascular Anesthesia, 2011, 25, 841-843.	0.6	5
99	A pilot audit of a protocol for ambulatory investigation of predicted low-risk patients with possible pulmonary embolism. Journal of the Royal College of Physicians of Edinburgh, The, 2011, 41, 196-201.	0.2	1
100	Inconsistencies in the planning of the duration of anticoagulation among outpatients with acute deep-vein thrombosis. Thrombosis and Haemostasis, 2011, 105, 239-244.	1.8	9
101	Venous thromboembolism in medical outpatients – a cross-sectional survey of risk assessment and prophylaxis. Thrombosis and Haemostasis, 2011, 105, 190-196.	1.8	26
102	Sustained impact of electronic alerts on rate of prophylaxis against venous thromboembolism. Thrombosis and Haemostasis, 2011, 106, 734-738.	1.8	23
103	Determination of age-specific and sex-specific familial risks for the different manifestations of venous thromboembolism: A nationwide family study in Sweden. Thrombosis and Haemostasis, 2011, 106, 102-112.	1.8	18
104	Disease burden and unmet needs for prevention of venous thromboembolism in medically ill patients in Europe show underutilisation of preventive therapies. Thrombosis and Haemostasis, 2011, 106, 600-608.	1.8	36

	Сітатіс	CITATION REPORT	
#	Article	IF	CITATIONS
105	New methods in diagnostic and therapy Catheter-directed pharmacomechanical thrombolysis for the management of deep vein thrombosis. Postepy W Kardiologii Interwencyjnej, 2011, 4, 311-316.	0.1	0
106	Current Status of the Korean Venous Thromboembolism Registry. Yonsei Medical Journal, 2011, 52, 558.	0.9	8
107	Deep-vein thrombosis: A United States cost model for a preventable and costly adverse event. Thrombosis and Haemostasis, 2011, 106, 405-415.	1.8	61
108	Imaging in thromboembolic disease. Imaging in Medicine, 2011, 3, 31-50.	0.0	0
109	Omission of Early Thromboprophylaxis and Mortality in Critically III Patients. Chest, 2011, 140, 1436-1446.	0.4	98
110	Diagnosing pulmonary embolism: a comparison of clinical probability scores. British Journal of Haematology, 2011, 153, 253-258.	1.2	4
111	Racial differences in venous thromboembolism. Journal of Thrombosis and Haemostasis, 2011, 9, 1877-1882.	1.9	191
112	Venous thromboembolism, statins and the protein unfolding response. International Journal of Clinical Practice, 2011, 65, 376-377.	0.8	0
113	The discovery and development of rivaroxaban. Annals of the New York Academy of Sciences, 2011, 1222, 64-75.	1.8	27
114	The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism. , 2011, 130, 46-58.		90
115	New parenteral anticoagulants in development. Therapeutic Advances in Cardiovascular Disease, 2011, 5, 33-59.	1.0	46
116	Combined magnetic resonance imaging of deep venous thrombosis and pulmonary arteries after a single injection of a blood pool contrast agent. European Radiology, 2011, 21, 318-325.	2.3	39
117	The AVAIL ME study: a multinational survey of VTE risk and prophylaxis. Journal of Thrombosis and Thrombolysis, 2011, 31, 47-56.	1.0	29
119	From proof to practice: innovations in total hip and total knee replacement—modern anticoagulation. European Orthopaedics and Traumatology, 2011, 2, 3-5.	0.1	0
120	Clinicians adopting evidence based guidelines: a case study with thromboprophylaxis. BMC Health Services Research, 2011, 11, 240.	0.9	18
121	MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism. Journal of Translational Medicine, 2011, 9, 159.	1.8	95
122	Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Medicine, 2011, 9, 1.	2.3	440
123	Endothelial-like cells in chronic thromboembolic pulmonary hypertension: crosstalk with myofibroblast-like cells. Respiratory Research, 2011, 12, 109.	1.4	53

#	Article	IF	CITATIONS
125	Economic burden of venous thromboembolism: a systematic review. Journal of Medical Economics, 2011, 14, 65-74.	1.0	124
127	An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement. Journal of Medical Economics, 2011, 14, 238-244.	1.0	11
128	Factors at Admission Associated With Bleeding Risk in Medical Patients. Chest, 2011, 139, 69-79.	0.4	347
129	The feasibility of catheter-directed thrombolysis for acute deep vein thrombosis: a regional perspective. Phlebology, 2011, 26, 94-101.	0.6	10
130	An observational study for venous thromboembolism risk assessment among hospitalized patients in general surgery clinics across Turkey. Phlebology, 2011, 26, 344-352.	0.6	5
131	Prevention of venous thromboembolism and safe use of heparin in Spanish hospitals. International Journal for Quality in Health Care, 2011, 23, 117-125.	0.9	0
132	Mortality from pulmonary embolism is decreasing in hospital patients. Journal of the Royal Society of Medicine, 2011, 104, 327-331.	1.1	22
133	Impact of venous thromboembolism on clinical management and therapy after hip and knee arthroplasty. Canadian Journal of Surgery, 2011, 54, 344-351.	0.5	54
134	Calculation of Human Femoral Vein Wall Parameters In Vivo From Clinical Data for Specific Patient. Journal of Biomechanical Engineering, 2012, 134, 124501.	0.6	1
135	Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ, The, 2012, 344, e3675-e3675.	3.0	204
136	ASHP Therapeutic Position Statement on the Role of Pharmacotherapy in Preventing Venous Thromboembolism in Hospitalized Patients. American Journal of Health-System Pharmacy, 2012, 69, 2174-2190.	0.5	12
137	What is the NHS Safety Thermometer?. Clinical Risk, 2012, 18, 163-169.	0.1	44
138	Thrombotic risks of oral contraceptives. Current Opinion in Obstetrics and Gynecology, 2012, 24, 235-240.	0.9	49
139	Clinical presentation and outcome of venous thromboembolism in COPD. European Respiratory Journal, 2012, 39, 862-868.	3.1	80
140	Thromboprophylaxis in Surgical and Medical Patients. Seminars in Respiratory and Critical Care Medicine, 2012, 33, 163-175.	0.8	22
141	Emerging Anticoagulants. Current Medicinal Chemistry, 2012, 19, 3388-3416.	1.2	13
142	Prophylaxis for Venous Thromboembolism: A Great Global Divide between Expert Guidelines and Clinical Practice?. Seminars in Thrombosis and Hemostasis, 2012, 38, 144-155.	1.5	26
143	Advances in oral anticoagulation treatment: the safety and efficacy of rivaroxaban in the prevention and treatment of thromboembolism. Therapeutic Advances in Hematology, 2012, 3, 309-323.	1.1	13

ARTICLE

144 Interventional Approaches in VTE Treatment (Vena Cava Filters, Catheter-Guided Thrombolysis,) Tj ETQq0 0 0 rgBT (Overlock 30 Tf 50 74

145	Pharmacokinetics, Biotransformation, and Mass Balance of Edoxaban, a Selective, Direct Factor Xa Inhibitor, in Humans. Drug Metabolism and Disposition, 2012, 40, 2250-2255.	1.7	169
146	Assessment of Venous Thromboembolism Risk and Adequacy of Prophylaxis in Selected Acute Care Medical Centres in Arabian Gulf States: Results from the ENDORSE Study. Medical Principles and Practice, 2012, 21, 522-528.	1.1	1
147	Is it time for home treatment of pulmonary embolism?. European Respiratory Journal, 2012, 40, 742-749.	3.1	36
148	Epidemiology, risk factors and sequelae of venous thromboembolism. Phlebology, 2012, 27, 2-11.	0.6	33
149	Multiple Sclerosis and Risk of Venous Thromboembolism: A Population-Based Cohort Study. Neuroepidemiology, 2012, 38, 76-83.	1.1	37
150	Management strategies for acute proximal deep vein thrombosis: a Delphi consensus. Phlebology, 2012, 27, 423-429.	0.6	1
151	Incidence and Risk Factors of the Post-thrombotic Syndrome. Phlebology, 2012, 27, 85-94.	0.6	25
152	Prevention and Treatment of Venous Thromboembolism and Pulmonary Embolism: The Role of Novel Oral Anticoagulants. Current Clinical Pharmacology, 2012, 7, 175-194.	0.2	4
153	Raising hematology's European voice: the importance of calling yourself a hematologist. Haematologica, 2012, 97, 476-478.	1.7	2
154	Pulmonary embolism: risk assessment and management. European Heart Journal, 2012, 33, 3014-3022.	1.0	118
155	Extended thromboprophylaxis for medically ill patients with decreased mobility: does it improve outcomes?. Journal of Thrombosis and Haemostasis, 2012, 10, 2053-2060.	1.9	23
156	The use of rivaroxaban for short- and long-term treatment of venous thromboembolism. Thrombosis and Haemostasis, 2012, 107, 1035-1043.	1.8	25
157	Use of biomarkers or echocardiography in pulmonary embolism: the Swiss Venous Thromboembolism Registry. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 1163-1169.	0.2	6
158	Shear Wave Elastography Quantification of Blood Elasticity During Clotting. Ultrasound in Medicine and Biology, 2012, 38, 2218-2228.	0.7	25
159	The role of urokinase plasminogen activator and plasmin activator inhibitor-1 on vein wall remodeling in experimental deep vein thrombosis. Journal of Vascular Surgery, 2012, 56, 1089-1097.	0.6	43
163	Long-term benefits of preventing venous thromboembolic events. Current Medical Research and Opinion, 2012, 28, 877-889.	0.9	13
164	Interventional treatment of venous thromboembolism: A review. Thrombosis Research, 2012, 129, 418-425.	0.8	46

#	Article	IF	CITATIONS
165	Venous thromboembolism prophylaxis in medical ICU patients in Asia (VOICE Asia): A multicenter, observational, cross-sectional study. Thrombosis Research, 2012, 129, e152-e158.	0.8	21
166	Opinions on mouse models of thrombosis. Thrombosis Research, 2012, 130, 285-286.	0.8	6
167	Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: Rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial. American Heart Journal, 2012, 163, 33-38.e1.	1.2	106
168	Venous thromboembolism prophylaxis of acutely ill hospitalized medical patients. Are we over-treating our patients?. European Journal of Internal Medicine, 2012, 23, 231-235.	1.0	3
169	Magnetic resonance VIBE venography using the blood pool contrast agent gadofosveset trisodium—An interrater reliability study. European Journal of Radiology, 2012, 81, 547-552.	1.2	34
170	A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting. BMC Health Services Research, 2012, 12, 192.	0.9	20
171	Thrombosis and cancer. Nature Reviews Clinical Oncology, 2012, 9, 437-449.	12.5	126
172	Awareness regarding venous thromboembolism among internal medicine practitioners in <scp>M</scp> exico: a national crossâ€sectional study. Internal Medicine Journal, 2012, 42, 1335-1341.	0.5	8
173	Risk of venous thromboembolism during treatment with antipsychotic agents. Psychiatry and Clinical Neurosciences, 2012, 66, 541-552.	1.0	36
174	Thrombolytic therapy for submassive pulmonary embolism. Best Practice and Research in Clinical Haematology, 2012, 25, 379-389.	0.7	17
175	Advances in the diagnosis and management of postthrombotic syndrome. Best Practice and Research in Clinical Haematology, 2012, 25, 391-402.	0.7	17
176	Venous thromboembolism: Epidemiology and magnitude of the problem. Best Practice and Research in Clinical Haematology, 2012, 25, 235-242.	0.7	176
177	Synthesis and structure–activity relationship of potent, selective and orally active anthranilamide-based factor Xa inhibitors: Application of weakly basic sulfoximine group as novel S4 binding element. European Journal of Medicinal Chemistry, 2012, 58, 136-152.	2.6	34
178	Effect of the Factor Xa Inhibitor Rivaroxaban on Arterial Thrombosis in Wild-Type and Apolipoprotein E-Deficient Mice. Thrombosis Research, 2012, 130, 793-798.	0.8	13
179	Managing venous thromboembolism in Asia: Winds of change in the era of new oral anticoagulants. Thrombosis Research, 2012, 130, 291-301.	0.8	16
180	Performance of five D-dimer assays for the exclusion of symptomatic distal leg vein thrombosis. Thrombosis and Haemostasis, 2012, 107, 369-378.	1.8	24
181	Venous thromboembolism: Annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates. Thrombosis and Haemostasis, 2012, 108, 291-302.	1.8	137
182	The treatment of venous thromboembolism with low-molecular-weight heparins. Thrombosis and Haemostasis, 2012, 107, 699-716.	1.8	17

#	Article	IF	Citations
183	Long-term attack rates, as compared with incidence rates, may provide improved cost-estimates in venous thromboembolism. A reply to S. D. Grosse. Thrombosis and Haemostasis, 2012, 107, 194-195.	1.8	4
184	Statins, inflammation and deep vein thrombosis: a systematic review. Journal of Thrombosis and Thrombolysis, 2012, 33, 371-382.	1.0	113
185	Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. Journal of Experimental Medicine, 2012, 209, 819-835.	4.2	1,441
186	Apixaban: an Oral Direct Factor-Xa Inhibitor. Advances in Therapy, 2012, 29, 187-201.	1.3	23
187	Coagulation Day 2010: an Austrian survey on the routine of thromboprophylaxis in intensive care. Intensive Care Medicine, 2012, 38, 984-990.	3.9	24
189	Prevention of venous thromboembolism in patients admitted to Australian hospitals: summary of National Health and Medical Research Council clinical practice guideline. Internal Medicine Journal, 2012, 42, 698-708.	0.5	48
190	Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thrombosis Journal, 2013, 11, 10.	0.9	141
191	Developing a complex intervention for the outpatient management of incidentally diagnosed pulmonary embolism in cancer patients. BMC Health Services Research, 2013, 13, 235.	0.9	10
192	Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism. International Journal of Emergency Medicine, 2013, 6, 25.	0.6	4
193	Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etexilate in Patients with Hepatic Impairment. Clinical Pharmacokinetics, 2013, 52, 243-254.	1.6	106
194	Microbial biosynthesis of the anticoagulant precursor 4-hydroxycoumarin. Nature Communications, 2013, 4, 2603.	5.8	130
195	Inferior vena cava filters: when, where, why?. Phlebology, 2013, 28, 177-179.	0.6	0
196	Incidence rate of symptomatic venous thromboembolic disease in patients from a medical care program in Buenos Aires, Argentina: a prospective cohort. Thrombosis Journal, 2013, 11, 16.	0.9	27
197	Anticoagulation with rivaroxaban: covering a broad spectrum of thromboembolic disease. Expert Review of Cardiovascular Therapy, 2013, 11, 817-828.	0.6	1
198	Factors Associated with elevated Pulmonary Arterial Pressure Levels on the Echocardiographic Assessment in Patients with Prior Pulmonary Embolism. Thrombosis Research, 2013, 131, e191-e195.	0.8	11
199	Anticoagulant and Antiplatelet Therapy. , 2013, , 643-667.		1
200	Association Between Obstructive Sleep Apnea and Pulmonary Embolism. Mayo Clinic Proceedings, 2013, 88, 579-587.	1.4	44
202	Clinical, demographic, and medicolegal factors associated with geographic variation in inferior vena cava filter utilization: An interstate analysis. Surgery, 2013, 153, 683-688.	1.0	41

#	Article	IF	CITATIONS
203	Toward the modelling of safety violations in healthcare systems. BMJ Quality and Safety, 2013, 22, 705-709.	1.8	18
204	Prevalence of venous thrombo-embolism in acute exacerbations of chronic obstructive pulmonary disease. The Egyptian Journal of Chest Diseases and Tuberculosis, 2013, 62, 557-566.	0.1	8
205	Adherence to and satisfaction with oral outpatient thromboembolism prophylaxis compared to parenteral: SALTO study. Revista Española De CirugÃa Ortopédica Y TraumatologÃa, 2013, 57, 53-60.	0.1	9
206	Incidence and diagnosis of pulmonary embolism in Northern Italy: A population-based study. European Journal of Internal Medicine, 2013, 24, e77-e78.	1.0	9
207	Venous Thrombo-embolism prophylaxis: Intermittent pneumatic compression. Reviews in Vascular Medicine, 2013, 1, 71-75.	0.4	3
209	Medical emergencies: pulmonary embolism and acute severe asthma. Anaesthesia, 2013, 68, 102-116.	1.8	9
210	Using a venous thromboembolism checklist significantly improves VTE prevention: a junior doctor led intervention. International Journal of Clinical Practice, 2013, 67, 157-160.	0.8	3
211	Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications. Expert Review of Cardiovascular Therapy, 2013, 11, 129-141.	0.6	36
212	Hematological and morphological investigation of thrombogenic mechanisms in the lungs of phenylhydrazine-treated rats. Experimental and Toxicologic Pathology, 2013, 65, 457-462.	2.1	13
213	Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. European Journal of Clinical Pharmacology, 2013, 69, 1617-1633.	0.8	81
214	Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosisâ€mediated conditions. Annals of the New York Academy of Sciences, 2013, 1291, 42-55.	1.8	18
215	Real-world economic burden of venous thromboembolism and antithrombotic prophylaxis in medical inpatients. Thrombosis Research, 2013, 131, 17-23.	0.8	25
216	Recent pharmacological advances for treating venous thromboembolism: are we witnessing the demise of warfarin?. Journal of the Royal Society of Medicine, 2013, 106, 441-446.	1.1	3
217	Fatal pulmonary embolism update: 10 years of autopsy experience at an academic medical center. JRSM Short Reports, 2013, 4, 204253331348982.	0.6	39
218	<i>In Vitro</i> Characterization of a Multifunctional Staphylokinase Variant with Reduced Reocclusion, Produced from Salt Inducible <i>E. coli</i> GJ1158. BioMed Research International, 2013, 2013, 1-12.	0.9	13
219	D-dimer plasma level: a reliable marker for venous thromboembolism after elective craniotomy. Journal of Neurosurgery, 2013, 119, 1340-1346.	0.9	30
220	Breakthroughs in hematology. Thalassemia Reports, 2013, 3, 1.	0.1	0
221	Venous thromboembolism prophylaxis audit in two Queensland hospitals. Internal Medicine Journal, 2013, 43, 560-566.	0.5	3

#	Article	IF	CITATIONS
222	Venous thrombosis risk assessment in medical inpatients: the medical inpatients and thrombosis (MITH) study. Journal of Thrombosis and Haemostasis, 2013, 11, 634-641.	1.9	40
223	Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ, The, 2013, 347, f5133-f5133.	3.0	158
224	Fatal venous thromboembolism associated with hospital admission: a cohort study to assess the impact of a national risk assessment target. Heart, 2013, 99, 1734-1739.	1.2	46
225	The incidence of pulmonary embolism during deep vein thrombosis. Phlebology, 2013, 28, 29-33.	0.6	38
226	Improving retrieval rates for retrievable inferior vena cava filters. Expert Review of Medical Devices, 2013, 10, 135-141.	1.4	14
227	Marine Sulfated Glycans with Serpin-Unrelated Anticoagulant Properties. Advances in Clinical Chemistry, 2013, 62, 269-303.	1.8	16
228	Clinical review: Inferior vena cava filters in the age of patient-centered outcomes. Annals of Medicine, 2013, 45, 474-481.	1.5	50
229	Potent Anticancer Actions of Omega-3 Polyunsaturated Fatty Acids of Marine Nutraceuticals � � � � � ï½² � ï½½ � ï½½ ï½½ ï½½ ï½½ ï½½ i²½² i²½² i²½² i²½	/2 ï;1/2 ï;1/2	₽ ⁄2 ⁄2 ⁄
230	Familial risk of venous thromboembolism in first-, second- and third-degree relatives: a nationwide family study in Sweden. Thrombosis and Haemostasis, 2013, 109, 458-463.	1.8	74
231	High incidence of venous thromboembolism despite electronic alerts for thromboprophylaxis in hospitalised cancer patients. Thrombosis and Haemostasis, 2013, 110, 184-190.	1.8	19
232	Predicting Short-term Mortality in Patients With Pulmonary Embolism: A Simple Model. American Journal of the Medical Sciences, 2013, 345, 462-469.	0.4	3
233	MANTRA: Mobile Anticoagulant Therapy Management. , 2013, , .		10
234	The results of aspiration thrombecomy in the endovascular treatment for iliofemoral deep vein thrombosis. [Chapchi] Journal Taehan Oekwa Hakhoe, 2013, 84, 292.	1.1	3
235	Lipid profile is associated with risk of thrombotic complications. Thrombosis and Haemostasis, 2013, 110, 390-392.	1.8	3
236	All-cause and disease-related health care costs associated with recurrent venous thromboembolism. Thrombosis and Haemostasis, 2013, 110, 1288-1297.	1.8	20
237	Understanding and managing deep vein thrombosis. NursePrescribing, 2013, 11, 390-395.	0.1	3
238	Efficacy and Toxicity of Factor Xa Inhibitors. Journal of Pharmacy and Pharmaceutical Sciences, 2013, 16, 74.	0.9	9
239	Symptoms and clinical relevance: A dilemma for clinical trials on prevention of venous thromboembolism. Thrombosis and Haemostasis, 2013, 109, 585-588.	1.8	12

#	Article	IF	Citations
240	Risk factors for venous thromboembolism and prophylaxis in medical inpatients: data from the FADOI â€~â€~GEMINI'' study. Italian Journal of Medicine, 0, , 23-31.	0.2	0
241	Multicentre validation of the Geneva Risk Score for hospitalised medical patients at risk of venous thromboembolism. Thrombosis and Haemostasis, 2014, 112, 531-538.	1.8	92
242	Identification of Reduced Circulating Haptoglobin Concentration as a Biomarker of the Severity of Pulmonary Embolism: A Nontargeted Proteomic Study. PLoS ONE, 2014, 9, e100902.	1.1	19
243	Non-Vitamin K Antagonist Oral Anticoagulants and the Treatment of Venous Thromboembolism in Cancer Patients: A Semi Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes. PLoS ONE, 2014, 9, e114445.	1.1	54
244	State of the art paper Clinical update on pulmonary embolism. Archives of Medical Science, 2014, 3, 557-565.	0.4	18
245	Respiratory Review of 2014: Pulmonary Thromboembolism. Tuberculosis and Respiratory Diseases, 2014, 77, 105.	0.7	Ο
246	Economic Analysis of Rivaroxaban for the Treatment and Long-Term Prevention of Venous Thromboembolism in Portugal. Acta Medica Portuguesa, 2014, 27, 615-624.	0.2	9
247	OPTIMAL PREVENTION OF HOSPITAL VENOUS THROMBOEMBOLISM WITH THE HELP OF MEDICAL INFORMATION SYSTEM. Rational Pharmacotherapy in Cardiology, 2014, 10, 425-431.	0.3	Ο
248	Thrombosis: A major contributor to global disease burden. Thrombosis and Haemostasis, 2014, 112, 843-852.	1.8	28
250	Prognosis of patients with suspected pulmonary embolism in Buenos Aires: a prospective cohort study. BMC Pulmonary Medicine, 2014, 14, 200.	0.8	4
251	Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders. Clinical Investigation, 2014, 4, 619-639.	0.0	2
252	Sticky Platelet Syndrome: History and Future Perspectives. Seminars in Thrombosis and Hemostasis, 2014, 40, 526-534.	1.5	32
253	Thrombosis: A major contributor to global disease burden. Thrombosis Research, 2014, 134, 931-938.	0.8	119
254	Direct oral anticoagulants: integration into clinical practice. Postgraduate Medical Journal, 2014, 90, 529-539.	0.9	15
255	Thrombosis: A Major Contributor to Global Disease Burden. Seminars in Thrombosis and Hemostasis, 2014, 40, 724-735.	1.5	103
256	lmagiologia cardÃaca no tromboembolismo pulmonar: avaliação da disfunção ventricular direita por Doppler tecidular. Revista Portuguesa De Cardiologia, 2014, 33, 597-598.	0.2	0
257	Endoscopy and the Risk of Venous Thromboembolism: A Case-Control Study. Endoscopy International Open, 2014, 2, E2-E5.	0.9	6
258	Alterations of lipid profile are a risk factor for venous thromboembolism and thrombotic complications. European Journal of Lipid Science and Technology, 2014, 116, 514-520.	1.0	1

#	Article	IF	CITATIONS
259	Implementing the Safety Thermometer tool in one NHS trust. British Journal of Nursing, 2014, 23, 268-272.	0.3	6
260	Oral anticoagulants: new and improved. Blood, 2014, 124, 1851-1852.	0.6	2
261	Thrombosis: a major contributor to the global disease burden. Journal of Thrombosis and Haemostasis, 2014, 12, 1580-1590.	1.9	343
262	Retrospective assessment of the utility of an ironâ€based agent for contrastâ€enhanced magnetic resonance venography in patients with endstage renal diseases. Journal of Magnetic Resonance Imaging, 2014, 40, 113-118.	1.9	46
264	PROF-ETEV study: prophylaxis of venous thromboembolic disease in critical care units in Spain. Intensive Care Medicine, 2014, 40, 1698-1708.	3.9	23
265	Venöse Thromboembolie. Wiener Klinische Wochenschrift Education, 2014, 9, 1-13.	0.0	0
266	Treatment options for venous thromboembolism: lessons learnt from clinical trials. Thrombosis Journal, 2014, 12, 27.	0.9	18
267	Long-term outcomes after pulmonary embolism. Blood Coagulation and Fibrinolysis, 2014, 25, 407-415.	0.5	49
268	Clinical and Safety Outcomes Associated With Treatment of Acute Venous Thromboembolism. JAMA - Journal of the American Medical Association, 2014, 312, 1122.	3.8	126
269	Risk-Adapted Management of Acute Pulmonary Embolism: Recent Evidence, New Guidelines. Rambam Maimonides Medical Journal, 2014, 5, e0040.	0.4	4
270	Laboratory Investigation of Thrombophilia / LABORATORIJSKO ISPITIVANJE TROMBOFILIJA. Journal of Medical Biochemistry, 2014, 33, 28-46.	0.7	5
271	Asthma and pulmonary embolism: bringing airways and vessels closer together. European Respiratory Journal, 2014, 43, 694-696.	3.1	5
272	Prevalence of Venous Thromboembolic Events and Diagnostic Performance of the Wells Score and Revised Geneva Scores for Pulmonary Embolism in Patients with Interstitial Lung Disease: A Prospective Study. Heart Lung and Circulation, 2014, 23, 778-785.	0.2	20
274	Symptomatic venous thromboembolism in orthognathic surgery and distraction osteogenesis: a retrospective cohort study of 4127 patients. British Journal of Oral and Maxillofacial Surgery, 2014, 52, 401-404.	0.4	11
275	Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: Efficacy and safety of non-VKA oral anticoagulants in selected populations. Thrombosis Research, 2014, 134, 227-233.	0.8	19
276	Rivaroxaban: A Review of Its Use in the Treatment of Deep Vein Thrombosis or Pulmonary Embolism and the Prevention of Recurrent Venous Thromboembolism. Drugs, 2014, 74, 243-262.	4.9	34
277	Managing pulmonary embolism from presentation to extended treatment. Thrombosis Research, 2014, 133, 139-148.	0.8	41
278	Antithrombotic and antidiabetic flavonoid glycosides from the grains of Sorghum bicolor (L.) Moench var. hwanggeumchal. Archives of Pharmacal Research, 2014, 37, 1394-1402.	2.7	16

#	Article	IF	CITATIONS
279	Cardiac imaging in pulmonary embolism: Assessment of right ventricular dysfunction by tissue Doppler. Revista Portuguesa De Cardiologia (English Edition), 2014, 33, 597-598.	0.2	0
280	Multilocus Genetic Risk Scores for Venous Thromboembolism Risk Assessment. Journal of the American Heart Association, 2014, 3, e001060.	1.6	58
281	Accuracy of nurseâ€performed compression ultrasonography in the diagnosis of proximal symptomatic deep vein thrombosis: a prospective cohort study. Journal of Thrombosis and Haemostasis, 2014, 12, 430-435.	1.9	15
282	On World Thrombosis Day. Lancet, The, 2014, 384, 1653-1654.	6.3	18
283	Clinical Use of Rivaroxaban: Pharmacokinetic and Pharmacodynamic Rationale for Dosing Regimens in Different Indications. Drugs, 2014, 74, 1587-1603.	4.9	40
284	Aspirin for the Prevention of Recurrent Venous Thromboembolism. Circulation, 2014, 130, 1062-1071.	1.6	232
285	Hormones and venous thromboembolism among postmenopausal women. Climacteric, 2014, 17, 34-37.	1.1	15
286	Management of venous thrombo-embolism: an update. European Heart Journal, 2014, 35, 2855-2863.	1.0	355
287	What is the clinical significance of isolated subsegmental pulmonary embolism?. Revista Portuguesa De Pneumologia, 2014, 20, 179-180.	0.7	1
289	Contraception for women with medical disorders. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2014, 28, 917-930.	1.4	1
290	Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2363-2371.	1.1	659
292	The VEINES-QOL/Sym questionnaire is a reliable and valid disease-specific quality of life measure for deep vein thrombosis in elderly patients. Quality of Life Research, 2014, 23, 2463-2471.	1.5	19
293	Phase III Trials of New Oral Anticoagulants in the Acute Treatment and Secondary Prevention of VTE: Comparison and Critique of Study Methodology and Results. Advances in Therapy, 2014, 31, 473-493.	1.3	32
294	Pharmacoeconomic Evaluation of Dabigatran, Rivaroxaban and Apixaban versus Enoxaparin for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement in Spain. Pharmacoeconomics, 2014, 32, 919-936.	1.7	20
295	Design, Synthesis, and Structure–Activity and Structure–Pharmacokinetic Relationship Studies of Novel [6,6,5] Tricyclic Fused Oxazolidinones Leading to the Discovery of a Potent, Selective, and Orally Bioavailable FXa Inhibitor. Journal of Medicinal Chemistry, 2014, 57, 7770-7791.	2.9	41
296	Enfermedad tromboembólica venosa idiopÃįtica versus secundaria. Revista Clinica Espanola, 2014, 214, 377-378.	0.2	0
297	The Postthrombotic Syndrome: Evidence-Based Prevention, Diagnosis, and Treatment Strategies. Circulation, 2014, 130, 1636-1661.	1.6	446
298	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal, 2014, 35, 3033-3080.	1.0	2,591

#	Article	IF	Citations
299	Bleeding and venous thromboembolism arising in acutely ill hospitalized medical patients. Findings from the Spanish National Discharge Database. European Journal of Internal Medicine, 2014, 25, 137-141.	1.0	8
301	The impact of risk assessment on the implementation of venous thromboembolism prophylaxis in foot and ankle surgery. Foot and Ankle Surgery, 2014, 20, 85-89.	0.8	44
302	External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR). Thrombosis and Haemostasis, 2014, 112, 692-699.	1.8	67
303	Epidemiology of first and recurrent venous thromboembolism: A population-based cohort study in patients without active cancer. Thrombosis and Haemostasis, 2014, 112, 255-263.	1.8	156
304	The management of acute venous thromboembolism in clinical practice – study rationale and protocol of the European PREFER in VTE Registry. Thrombosis Journal, 2015, 13, 41.	0.9	40
305	Extracellular DNA and histones: doubleâ€edged swords in immunothrombosis. Journal of Thrombosis and Haemostasis, 2015, 13, S82-S91.	1.9	170
306	Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusaiâ€VTE trial. Journal of Thrombosis and Haemostasis, 2015, 13, 1606-1614.	1.9	44
307	The Utility of Hybrid SPECT/CT Lung Perfusion Scintigraphy in Pulmonary Embolism Diagnosis. Respiration, 2015, 90, 393-401.	1.2	27
308	Epidemiology and pathophysiology of venous thromboembolism: similarities with atherothrombosis and the role of inflammation. Thrombosis and Haemostasis, 2015, 113, 1176-1183.	1.8	101
309	Dietary omega-3 alpha-linolenic acid does not prevent venous thrombosis in mice. Thrombosis and Haemostasis, 2015, 113, 177-184.	1.8	12
310	Diagnosing Acute Pulmonary Embolism With Computed Tomography. Journal of Thoracic Imaging, 2015, 30, 176-192.	0.8	26
311	PERC rule to exclude the diagnosis of pulmonary embolism in emergency low-risk patients: study protocol for the PROPER randomized controlled study. Trials, 2015, 16, 537.	0.7	12
312	Use of rivaroxaban in an elderly patient with intermediate-low early mortality risk due to pulmonary embolism: a case report. Journal of Medical Case Reports, 2015, 9, 274.	0.4	2
313	Design, Synthesis, and Biological Evaluation of Dabigatran Etexilate Mimics, a Novel Class of Thrombin Inhibitors. Archiv Der Pharmazie, 2015, 348, 595-605.	2.1	7
314	Diagnostic performance of magnetic resonance imaging forÂacute pulmonary embolism: a systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2015, 13, 1623-1634.	1.9	20
315	Results of Surgery in General Surgical Patients Receiving Warfarin: Retrospective Analysis of 61 Patients. International Surgery, 2015, 100, 225-232.	0.0	11
316	The Value of Electrocardiographic Abnormalities in the Prognosis of Pulmonary Embolism: A Consensus Paper. Annals of Noninvasive Electrocardiology, 2015, 20, 207-223.	0.5	50
317	Preoperative Hospitalization Is Independently Associated With Increased Risk for Venous Thromboembolism in Patients Undergoing Colorectal Surgery. Diseases of the Colon and Rectum, 2015, 58, 782-791.	0.7	16

#	Article	IF	CITATIONS
318	Emerging applications for ferumoxytol as a contrast agent in MRI. Journal of Magnetic Resonance Imaging, 2015, 41, 884-898.	1.9	307
319	Critical appraisal of dabigatran in the treatment of deep vein thrombosis and pulmonary embolism. Journal of Blood Medicine, 2015, 6, 177.	0.7	2
320	Review of the cost of venous thromboembolism. ClinicoEconomics and Outcomes Research, 2015, 7, 451.	0.7	128
321	Mobilisation after Lower Limb Deep Vein Thrombosis and Post-Thrombotic Syndrome. Journal of Novel Physiotherapies, 2015, 05, .	0.1	0
322	Acute phase treatment of venous thromboembolism: advanced therapy. Thrombosis and Haemostasis, 2015, 113, 1202-1209.	1.8	5
323	Cost-effectiveness of new oral anticoagulants in the treatment and secondary prevention of venous thromboembolism. Rational Pharmacotherapy in Cardiology, 2015, 11, 496-503.	0.3	2
324	Prospective Evaluation of Weight-Based Prophylactic Enoxaparin Dosing in Critically Ill Trauma Patients: Adequacy of AntiXa Levels is Improved. American Surgeon, 2015, 81, 605-609.	0.4	56
325	Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. PLoS ONE, 2015, 10, e0144856.	1.1	140
326	Thrombosis: Novel nanomedical concepts of diagnosis and treatment. World Journal of Cardiology, 2015, 7, 434.	0.5	27
327	Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist. Thrombosis Journal, 2015, 13, 20.	0.9	37
328	Tromboembolismo pulmonar. Medicine, 2015, 11, 5245-5253.	0.0	0
329	Diagnosis of pulmonary embolism. Presse Medicale, 2015, 44, e385-e391.	0.8	8
330	Rationale and design of three observational, prospective cohort studies including biobanking to evaluate and improve diagnostics, management strategies and risk stratification in venous thromboembolism: the <i>VTEval Project</i> . BMJ Open, 2015, 5, e008157.	0.8	19
331	Percutaneous pharmacomechanical thrombectomy for acute iliofemoral deep vein thrombosis: A suitability study. Phlebology, 2015, 30, 235-241.	0.6	4
332	Litigation claims relating to venous thromboembolism in the NHS. Phlebology, 2015, 30, 389-396.	0.6	10
333	Direct factor Xa inhibitor edoxaban: from bench to clinical practice. Expert Review of Hematology, 2015, 8, 707-725.	1.0	1
334	Economic Burden of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery. Value in Health Regional Issues, 2015, 6, 73-79.	0.5	5
335	Right Ventricular Echocardiographic Parameters Are Associated with Mortality after Acute Pulmonary Embolism. Journal of the American Society of Echocardiography, 2015, 28, 355-362.	1.2	69

#	Article	IF	Citations
336	Time trends in pulmonary embolism mortality in France, 2000-2010. Thrombosis Research, 2015, 135, 334-338.	0.8	17
339	Pharmacotherapy with oral Xa inhibitors for venous thromboembolism. Expert Opinion on Pharmacotherapy, 2015, 16, 645-658.	0.9	12
340	Epidemiology of venous thromboembolism. Nature Reviews Cardiology, 2015, 12, 464-474.	6.1	783
341	Prevention of venous thromboembolism in the critically ill patient. Journal of the Intensive Care Society, 2015, 16, 199-201.	1.1	4
342	Clinical Assessment of Endovascular Stenting Compared with Compression Therapy Alone in Post-thrombotic Patients with lliofemoral Obstruction. European Journal of Vascular and Endovascular Surgery, 2015, 50, 101-107.	0.8	44
343	Hemodynamic significance of collateral blood flow in chronic venous obstruction. Phlebology, 2015, 30, 27-34.	0.6	12
344	Endovascular management of proximal lower limb deep venous thrombosis – A prospective study with six-month follow-up. Phlebology, 2015, 30, 441-448.	0.6	6
345	Effect of anticoagulant treatment in deep vein thrombosis: A patient-specific computational fluid dynamics study. Journal of Biomechanics, 2015, 48, 2047-2053.	0.9	11
346	Diuretic versus placebo in normotensive acute pulmonary embolism with right ventricular enlargement and injury: a double-blind randomised placebo controlled study. Protocol of the DiPER study. BMJ Open, 2015, 5, e007466-e007466.	0.8	11
347	Screening for Occult Cancer in Unprovoked Venous Thromboembolism. New England Journal of Medicine, 2015, 373, 697-704.	13.9	239
348	Inhospital mortality among clinical and surgical inpatients recently diagnosed with venous thromboembolic disease. Journal of Thrombosis and Thrombolysis, 2015, 40, 225-230.	1.0	8
349	Adecuación de tromboprofilaxis en pacientes médicos hospitalizados en AndalucÃa. Estudio multicéntrico. Revista Clinica Espanola, 2015, 215, 141-147.	0.2	9
351	Assessment of thromboprophylaxis in medical patients hospitalized in Andalusia. A multicenter study. Revista Clínica Espanõla, 2015, 215, 141-147.	0.3	2
352	Inferior vena cava filters: current best practices. Journal of Thrombosis and Thrombolysis, 2015, 39, 315-327.	1.0	15
353	Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program. Thrombosis Journal, 2015, 13, 2.	0.9	90
354	Practical Management of Rivaroxaban for the Treatment of Venous Thromboembolism. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 309-318.	0.7	3
355	The CIRSE Retrievable IVC Filter Registry: Retrieval Success Rates in Practice. CardioVascular and Interventional Radiology, 2015, 38, 1502-1507.	0.9	57
356	The relation between platelet-to-lymphocyte ratio and Pulmonary Embolism Severity Index in acute pulmonary embolism. Heart and Lung: Journal of Acute and Critical Care, 2015, 44, 340-343.	0.8	39

#	Article	IF	CITATIONS
357	Evaluation Factors of Pulmonary Embolism Severity and Prognosis. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 273-284.	0.7	4
358	The early management of DVT in the North West of England: A nation-wide problem?. Thrombosis Research, 2015, 136, 76-86.	0.8	15
359	Current management of venous thromboembolism in Japan: Current epidemiology and advances in anticoagulant therapy. Journal of Cardiology, 2015, 66, 451-459.	0.8	65
360	Venous thrombosis. Nature Reviews Disease Primers, 2015, 1, 15006.	18.1	216
361	Haematological considerations in urology: A systematic review. Journal of Clinical Urology, 2015, 8, 321-328.	0.1	3
362	Endovascular Management of Deep Vein Thrombosis with Rheolytic Thrombectomy: Final Report of the Prospective Multicenter PEARL (Peripheral Use of AngioJet Rheolytic Thrombectomy with a Variety of) Tj ETQq1 1	007.84314	⊦rgB∏ /Overl
364	Venous thromboembolism: identifying patients at risk and establishing prophylaxis. Current Medical Research and Opinion, 2015, 31, 2297-2311.	0.9	10
366	Rivaroxaban in preventing venous thromboembolism after arthroplastic surgery in Taiwan. Kaohsiung Journal of Medical Sciences, 2015, 31, 534-539.	0.8	4
367	Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose–response meta-analysis and network meta-analysis. Thrombosis Research, 2015, 136, 1133-1144.	0.8	55
368	Rate and duration of hospitalization for deep vein thrombosis and pulmonary embolism in real-world clinical practice. Annals of Medicine, 2015, 47, 546-554.	1.5	33
369	Pulmonary embolism: An update. Presse Medicale, 2015, 44, e373-e376.	0.8	1
370	Venous thromboembolism prevention and treatment: expanding the rivaroxaban knowledge base with real-life data. European Heart Journal Supplements, 2015, 17, D32-D41.	0.0	10
371	Point-of-care ultrasound in the diagnosis of pulmonary embolism. The Ultrasound Journal, 2015, 7, 7.	2.0	39
372	Contraceptive and hormonal treatment options for women with history of venous thromboembolism. BMJ, The, 2015, 351, h4847.	3.0	17
373	Molecular modeling studies of [6,6,5] Tricyclic Fused Oxazolidinones as FXa inhibitors using 3D-QSAR, Topomer CoMFA, molecular docking and molecular dynamics simulations. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4522-4528.	1.0	22
374	Research progress in the application of inferior vena cava filter on acute venous thrombosis. Journal of Acute Disease, 2015, 4, 97-100.	0.0	0
376	Are Higher Hospital Venous Thromboembolism Rates an Indicator of Better Quality?. Advances in Surgery, 2015, 49, 185-204.	0.6	7
377	Developments in the management and treatment of pulmonary embolism. European Respiratory Review, 2015, 24, 484-497.	3.0	20

#	Article	IF	CITATIONS
378	Dosing of rivaroxaban by indication: getting the right dose for the patient. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1665-1677.	1.5	3
379	Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deepâ€Vein Thrombosis as Firstâ€Line Therapy (AMPLIFY) Trial. Journal of the American Heart Association, 2015, 4, .	1.6	27
380	Pulmonary embolism: Epidemiology and registries. Presse Medicale, 2015, 44, e377-e383.	0.8	20
381	Design, synthesis and antithrombotic evaluation of novel dabigatran etexilate analogs, a new series of non-peptides thrombin inhibitors. Bioorganic and Medicinal Chemistry, 2015, 23, 7405-7416.	1.4	6
382	Rivaroxaban in the Treatment of Venous Thromboembolism and the Prevention of Recurrences. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 297-308.	0.7	6
383	Efficacy and safety of the new oral anticoagulants in the treatment of venous thromboembolic complications: meta-analysis. Rational Pharmacotherapy in Cardiology, 2016, 12, 31-39.	0.3	3
384	THE ADVANCED TACTICS OF THE MANAGEMENT OF PATIENTS WITH VENOUS THROMBOEMBOLISM: THE ROLE OF RIVAROXABAN AT VARIOUS STAGES OF TREATMENT. Rational Pharmacotherapy in Cardiology, 2016, 12, 337-343.	0.3	1
385	New anticoagulants for the treatment of venous thromboembolism. Jornal Brasileiro De Pneumologia, 2016, 42, 146-154.	0.4	27
386	Alternative diagnoses based on CT angiography of the chest in patients with suspected pulmonary thromboembolism. Jornal Brasileiro De Pneumologia, 2016, 42, 35-41.	0.4	12
387	Effective management of venous thromboembolism in the community: non-vitamin K antagonist oral anticoagulants. International Journal of General Medicine, 2016, 9, 107.	0.8	4
388	Limited evidence on persistence with anticoagulants, and its effect on the risk of recurrence of venous thromboembolism: a systematic review of observational studies. Patient Preference and Adherence, 2016, Volume 10, 1657-1665.	0.8	11
389	Elevated risk of venous thromboembolic events in patients with inflammatory myopathies. Vascular Health and Risk Management, 2016, 12, 233.	1.0	11
390	Updates on Advanced Therapies for Acute Pulmonary Embolism. International Journal of Cardiovascular Practice, 2016, 1, 1-4.	0.2	8
391	Anticoagulant effect and safety assessment of an aqueous extract of Pseudocedrela kotschyi (Schweinf.) Harms and Adenia cissampeloides (Planch. Ex Hook.) Harms. Journal of Intercultural Ethnopharmacology, 2016, 5, 153.	0.9	6
392	Venous thromboembolism: A Call for risk assessment in all hospitalised patients. Thrombosis and Haemostasis, 2016, 116, 777-779.	1.8	29
393	European Union-28: An annualised cost-of-illness model for venous thromboembolism. Thrombosis and Haemostasis, 2016, 115, 800-808.	1.8	85
394	Multifaceted Intervention to Prevent Venous Thromboembolism in Patients Hospitalized for Acute Medical Illness: A Multicenter Cluster-Randomized Trial. PLoS ONE, 2016, 11, e0154832.	1.1	21
395	Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis, PLoS ONF, 2016, 11, e0160064	1.1	51

#	Article	IF	CITATIONS
396	Familial Clustering of Venous Thromboembolism – A Danish Nationwide Cohort Study. PLoS ONE, 2016, 11, e0169055.	1.1	1
397	Risk factors for venous thromboembolism in women under combined oral contraceptive. Thrombosis and Haemostasis, 2016, 115, 135-142.	1.8	35
398	Current incidence of venous thromboembolism and comparison with 1998: a community-based study in Western France. Thrombosis and Haemostasis, 2016, 116, 967-974.	1.8	96
399	Global Anticoagulant Registry in the Field – Venous Thromboembolism (GARFIELD-VTE). Thrombosis and Haemostasis, 2016, 116, 1172-1179.	1.8	46
400	Trends in incidence versus case fatality rates of pulmonary embolism: Good news or bad news?. Thrombosis and Haemostasis, 2016, 115, 233-235.	1.8	29
401	Short-Term Anticoagulant Therapy and Thrombus Location Are Independent Risk Factors for Delayed Recanalization of Deep Vein Thrombosis. Medical Science Monitor, 2016, 22, 219-225.	0.5	9
402	Deep vein thrombosis and pulmonary embolism. Lancet, The, 2016, 388, 3060-3073.	6.3	572
403	Epidemiology of venous thromboembolism in the Framingham Heart Study. Thrombosis Research, 2016, 145, 27-33.	0.8	94
404	Association between thyroid dysfunction and venous thromboembolism in the elderly: a prospective cohort study. Journal of Thrombosis and Haemostasis, 2016, 14, 685-694.	1.9	16
405	Electrical muscle stimulation in thomboprophylaxis: review and a derived hypothesis about thrombogenesis—the 4th factor. SpringerPlus, 2016, 5, 884.	1.2	11
406	Health-related quality of life after deep vein thrombosis. SpringerPlus, 2016, 5, 1278.	1.2	36
407	Prognostic value of prior heart failure in patients admitted with acute pulmonary thromboembolism. Medicina ClÂnica (English Edition), 2016, 147, 340-344.	0.1	0
408	Comparison of three different anti-Xa assays in major orthopedic surgery patients treated with fondaparinux. International Journal of Hematology, 2016, 103, 554-559.	0.7	6
410	A Comprehensive Overview of Direct Oral Anticoagulants for the Management of Venous Thromboembolism. American Journal of the Medical Sciences, 2016, 352, 92-106.	0.4	21
412	Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. New England Journal of Medicine, 2016, 375, 534-544.	13.9	379
413	Clinical factors associated with inappropriate prophylaxis of venous thromboembolic disease in critically ill patients. A single day cross-sectional study. Thrombosis Research, 2016, 143, 111-117.	0.8	4
414	Molecular design, synthesis and anticoagulant activity evaluation of fluorinated dabigatran analogues. Bioorganic and Medicinal Chemistry, 2016, 24, 2739-2753.	1.4	8
415	Global Burden of Thrombosis. Circulation Research, 2016, 118, 1340-1347.	2.0	784

#	Article	IF	CITATIONS
416	Effectiveness of Intermittent Pneumatic Compression Devices for Venous Thromboembolism Prophylaxis in High-Risk Surgical Patients: A Systematic Review. Journal of Arthroplasty, 2016, 31, 524-532.	1.5	65
417	Using the laboratory to predict thrombosis in dogs: An achievable goal?. Veterinary Journal, 2016, 215, 10-20.	0.6	13
418	Treatment of Venous Thromboembolism With New Anticoagulant Agents. Journal of the American College of Cardiology, 2016, 67, 1941-1955.	1.2	63
419	Prophylactic heparin in acute intracerebral hemorrhage: a propensity score-matched analysis of the INTERACT2 study. International Journal of Stroke, 2016, 11, 549-556.	2.9	12
420	Evaluating antithrombotic activity of HY023016 on rat hypercoagulable model. European Journal of Pharmacology, 2016, 781, 190-197.	1.7	2
421	Controversies in venous thromboembolism: the unique case of isolated distal deep vein thrombosis. Internal and Emergency Medicine, 2016, 11, 775-779.	1.0	13
422	Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood, 2016, 127, 2035-2037.	0.6	47
423	In vitro evaluation of clot capture efficiency of an absorbable vena cava filter. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2016, 4, 472-478.	0.9	7
425	Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease. Expert Opinion on Pharmacotherapy, 2016, 17, 2033-2047.	0.9	4
427	Economic burden of venous thromboembolism: Are novel oral anticaoagulants the possible solution?. International Journal of Cardiology, 2016, 220, 551-552.	0.8	1
428	Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study. Journal of Thrombosis and Thrombolysis, 2016, 42, 600-609.	1.0	50
429	Echocardiography does not predict mortality in hemodynamically stable elderly patients with acute pulmonary embolism. Thrombosis Research, 2016, 145, 67-71.	0.8	11
430	Population Pharmacokinetic and Pharmacodynamic Modeling Analysis of GCCâ€4401C, a Novel Direct Factor Xa Inhibitor, in Healthy Volunteers. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 532-543.	1.3	11
431	Metabolic Influences on Risk for Tendon Disorders. Advances in Experimental Medicine and Biology, 2016, , .	0.8	16
432	Symptomatology, Clinical Presentation and Basic Work up in Patients with Suspected Pulmonary Embolism. Advances in Experimental Medicine and Biology, 2016, 906, 33-48.	0.8	5
433	The management of patients with venous thromboembolism in Italy: insights from the PREFER in VTE registry. Internal and Emergency Medicine, 2016, 11, 1095-1102.	1.0	5
434	Successful use of rivaroxaban in postoperative deep vein thrombosis of the lower limb following instability with warfarin: a case report. Journal of Medical Case Reports, 2016, 10, 276.	0.4	2
435	The values of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in predicting 30Âday mortality in patients with acute pulmonary embolism. BMC Cardiovascular Disorders, 2016, 16, 123.	0.7	36

	CHAIL	ON REPORT	
#	Article	IF	Citations
436	Betrixaban – the next direct factor Xa inhibitor?. Expert Review of Hematology, 2016, 9, 1111-1117.	1.0	15
437	Rivaroxaban for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis with trial sequential analysis of randomized controlled trials. Scientific Reports, 2016, 6, 23726.	1.6	38
438	External validation of the IMPROVE Bleeding Risk Assessment Model in medical patients. Thrombosis and Haemostasis, 2016, 116, 530-536.	1.8	47
439	The impact of the DoH Commissioning for Quality and Innovation incentive on the success of venous thromboembolism risk assessment in hospitalised patients. A single institution experience in a quality outcome improvement over a 4-year cycle. JRSM Open, 2016, 7, 205427041663270.	0.2	2
440	Medical Misadventure. , 2016, , 514-519.		0
441	Prevention of hospital-acquired thrombosis from a primary care perspective: a qualitative study. British Journal of General Practice, 2016, 66, e593-e602.	0.7	3
442	Five-year follow-up of pulmonary embolism under anticoaugulation. Medicine (United States), 2016, 95, e4364.	0.4	8
443	Thromboembolic disease and breathlessness. Current Opinion in Supportive and Palliative Care, 2016, 10, 249-255.	0.5	3
444	Numerical simulations of a reduced model for blood coagulation. Zeitschrift Fur Angewandte Mathematik Und Physik, 2016, 67, 1.	0.7	7
445	Non-vitamin K antagonist oral anticoagulants for the prevention of recurrent venous thromboembolism. Thrombosis Research, 2016, 144, 12-20.	0.8	5
446	Drug Treatment of Venous Thromboembolism in the Elderly. Drugs and Aging, 2016, 33, 475-490.	1.3	6
447	Contemporary developments in the discovery of selective factor Xa inhibitors: A review. European Journal of Medicinal Chemistry, 2016, 121, 671-698.	2.6	41
448	Catheter-directed thrombolysis: is it worth the risk?. Lancet Haematology,the, 2016, 3, e54-e55.	2.2	1
450	Intravenous pressure changes in patients with postthrombotic deep venous obstruction: results using a treadmill stress test. Journal of Thrombosis and Haemostasis, 2016, 14, 1163-1170.	1.9	26
451	Cost-of-illness model for venous thromboembolism. Thrombosis Research, 2016, 145, 130-132.	0.8	12
452	Echocardiographic Diagnosis of Acute Pulmonary Embolism in Patients with McConnell's Sign. Echocardiography, 2016, 33, 696-702.	0.3	27
453	Rediscussing Anticoagulation in Distal Deep Venous Thrombosis. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 772-778.	0.7	13
454	Prophylaxis of Venous Thrombosis in Neurocritical Care Patients: An Evidence-Based Guideline: A Statement for Healthcare Professionals from the Neurocritical Care Society. Neurocritical Care, 2016, 24, 47-60.	1.2	125

#	Article	IF	CITATIONS
455	Prior thromboprophylaxis and outcome in patients experiencing acute venous thromboembolism after an acute medical illness. European Journal of Internal Medicine, 2016, 30, 72-76.	1.0	5
456	Validation of the International Medical Prevention Registry on Venous Thromboembolism Bleeding Risk Score. Chest, 2016, 149, 372-379.	0.4	61
457	Heart failure and risk of venous thromboembolism: a systematic review and meta-analysis. Lancet Haematology,the, 2016, 3, e30-e44.	2.2	59
458	Rivaroxaban versus standard of care in venous thromboembolism prevention following hip or knee arthroplasty in daily clinical practice (Spanish data from the international study XAMOS). Revista Española De CirugÃa Ortopédica Y TraumatologÃa, 2016, 60, 44-52.	0.1	1
459	Incidence of venous thromboembolism in COPD: linking inflammation and thrombosis?. European Respiratory Journal, 2016, 47, 369-373.	3.1	21
460	Anticoagulant therapy after venous thromboembolism and 10-year mortality. International Journal of Cardiology, 2016, 208, 72-78.	0.8	16
461	Recent advances in the management of pulmonary embolism: focus on the critically ill patients. Annals of Intensive Care, 2016, 6, 19.	2.2	39
462	Oral and inhaled corticosteroid use and risk of recurrent pulmonary embolism. Thrombosis Research, 2016, 140, 46-50.	0.8	14
464	Fibrin-related markers for diagnosing acute-, subclinical-, and pre-venous thromboembolism in patients with major orthopedic surgery. International Journal of Hematology, 2016, 103, 560-566.	0.7	15
465	Contemporary management of acute and chronic deep venous thrombosis. British Medical Bulletin, 2016, 117, 107-120.	2.7	22
466	Individually tailored contrast enhancement in CT pulmonary angiography. British Journal of Radiology, 2016, 89, 20150850.	1.0	30
467	Role of clinical and pulmonary computed tomography angiographic parameters in the prediction of short- and long-term mortality in patients with pulmonary embolism. Internal and Emergency Medicine, 2016, 11, 405-413.	1.0	14
468	Enoxaparin Treatment Followed by Rivaroxaban for the Treatment of Acute Lower Limb Venous Thromboembolism. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 377-380.	0.7	4
470	Assessment of Venous Thrombosis in Animal Models. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 245-252.	1.1	21
472	Role of Physical Therapists in the Management of Individuals at Risk for or Diagnosed With Venous Thromboembolism: Evidence-Based Clinical Practice Guideline. Physical Therapy, 2016, 96, 143-166.	1.1	38
473	Direct Oral Anticoagulants and Their Use in Treatment and Secondary Prevention of Acute Symptomatic Venous Thromboembolism. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 209-221.	0.7	5
474	Competitive assessments of pulmonary embolism: Noninvasiveness versus the golden standard. Vascular, 2016, 24, 217-224.	0.4	3
475	Current standings in diagnostic management of acute venous thromboembolism: Still rough around the edges. Blood Reviews, 2016, 30, 21-26.	2.8	20

#	Article	IF	CITATIONS
477	Pulmonary embolism requiring intensive care: Do we now have a better idea of how to triage?. Respirology, 2017, 22, 213-214.	1.3	3
478	Prothrombotic Fibrin Clot Phenotype Is Associated With Recurrent Pulmonary Embolism After Discontinuation of Anticoagulant Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 365-373.	1.1	45
479	Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association. Circulation, 2017, 135, e146-e603.	1.6	7,085
481	First <i>in vivo</i> magnetic particle imaging of lung perfusion in rats. Physics in Medicine and Biology, 2017, 62, 3510-3522.	1.6	88
483	Clinical characteristics associated with diagnostic delay of pulmonary embolism in primary care: a retrospective observational study. BMJ Open, 2017, 7, e012789.	0.8	26
484	Whole Exome Sequencing Reveals Severe Thrombophilia in Acute Unprovoked Idiopathic Fatal Pulmonary Embolism. EBioMedicine, 2017, 17, 95-100.	2.7	13
485	Net clinical benefit of hospitalization versus outpatient management of patients with acute pulmonary embolism. Journal of Thrombosis and Haemostasis, 2017, 15, 685-694.	1.9	41
486	Risk-adapted management of pulmonary embolism. Thrombosis Research, 2017, 151, S92-S96.	0.8	18
487	Diagnostic accuracy of magnetic resonance imaging in patients with suspected pulmonary embolism: A bivariate meta-analysis. Thrombosis Research, 2017, 154, 64-72.	0.8	11
488	Pulmonary embolism related sudden cardiac arrest admitted alive at hospital: Management and outcomes. Resuscitation, 2017, 115, 135-140.	1.3	31
489	Screening for occult cancer in idiopathic venous thromboembolism — Systemic review and meta-analysis. European Journal of Internal Medicine, 2017, 42, 74-80.	1.0	9
490	Testosterone Treatment and Cardiovascular and Venous Thromboembolism Risk: What is â€~New'?. Journal of Investigative Medicine, 2017, 65, 964-973.	0.7	46
491	Transthoracic Echocardiography for Diagnosing Pulmonary Embolism: A Systematic Review and Meta-Analysis. Journal of the American Society of Echocardiography, 2017, 30, 714-723.e4.	1.2	119
492	ABO blood types associated with the risk of venous thromboembolism in Han Chinese people: A hospital-based study of 200,000 patients. Scientific Reports, 2017, 7, 42925.	1.6	15
493	Pharmacological management of pulmonary embolism. Expert Opinion on Pharmacotherapy, 2017, 18, 79-93.	0.9	3
494	Factors Influencing Hospital Stay for Pulmonary Embolism. A Cohort Study. Archivos De Bronconeumologia, 2017, 53, 432-436.	0.4	3
495	Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands. Journal of Medical Economics, 2017, 20, 813-824.	1.0	14
496	Ultrasound-facilitated, catheter-directed, low-dose fibrinolysis in elderly patients with pulmonary embolism: A SEATTLE II sub-analysis. Vascular Medicine, 2017, 22, 324-330.	0.8	3

#	Article	IF	CITATIONS
497	Factores que influyen en la estancia hospitalaria por embolia pulmonar. Un estudio de cohortes. Archivos De Bronconeumologia, 2017, 53, 432-436.	0.4	3
498	Quality of Life, Dyspnea, and Functional Exercise Capacity Following a First Episode of Pulmonary Embolism: Results of the ELOPE Cohort Study. American Journal of Medicine, 2017, 130, 990.e9-990.e21.	0.6	107
499	Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. New England Journal of Medicine, 2017, 376, 1211-1222.	13.9	577
500	Time trends in incidence rates of venous thromboembolism in a large cohort recruited from the general population. European Journal of Epidemiology, 2017, 32, 299-305.	2.5	76
501	The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous) Tj ETQq0 0 Journal, 2017, 185, 93-100.	0 rgBT /0 1.2	verlock 10 Tf 48
502	Functional and Exercise Limitations After a First Episode of Pulmonary Embolism. Chest, 2017, 151, 1058-1068.	0.4	192
503	Prophylaxis of venous thromboembolism – The guidelines are there. Revista Portuguesa De Cardiologia (English Edition), 2017, 36, 617-618.	0.2	0
504	Diagnostic Accuracy of Point-of-Care Ultrasound Performed by Pulmonary Critical Care Physicians for Right Ventricle Assessment in Patients With Acute Pulmonary Embolism*. Critical Care Medicine, 2017, 45, 2040-2045.	0.4	22
505	Venous thromboembolism risks and prophylaxis in King Fahad Hospital, Madinah, Saudi Arabia. Journal of Epidemiology and Global Health, 2017, 7, 295.	1.1	5
506	Awareness of venous thromboembolism and thromboprophylaxis among hospitalized patients: a cross-sectional study. Thrombosis Journal, 2017, 15, 19.	0.9	26
507	Comparison of three different anti-Xa assays in major orthopedic surgery patients treated with direct oral anticoagulant. Thrombosis Journal, 2017, 15, 27.	0.9	3
511	Diagnosis and Management of Pulmonary Embolism in the Hospitalized Patient. Hospital Medicine Clinics, 2017, 6, 517-531.	0.2	0
512	Inferior Vena Cava Filters to Prevent Pulmonary Embolism. Journal of the American College of Cardiology, 2017, 70, 1587-1597.	1.2	134
513	Prescribing Errors With Low-Molecular-Weight Heparins. Journal of Patient Safety, 2017, Publish Ahead of Print, e587-e592.	0.7	6
514	Prevenção do tromboembolismo venoso – as recomendações estão aÃ…. Revista Portuguesa De Cardiologia, 2017, 36, 617-618.	0.2	0
515	Detailed assessment of benefits and risks of retrievable inferior vena cava filters on patients with complicated injuries: the da Vinci multicentre randomised controlled trial study protocol. BMJ Open, 2017, 7, e016747.	0.8	12
516	Statins and venous thromboembolism: do they represent a viable therapeutic agent?. Expert Review of Cardiovascular Therapy, 2017, 15, 629-637.	0.6	7
517	Serum C-reactive protein increases the risk of venous thromboembolism: a prospective study and meta-analysis of published prospective evidence. European Journal of Epidemiology, 2017, 32, 657-667.	2.5	59

#	Article	IF	CITATIONS
518	Risk of recurrent venous thromboembolism in COPD patients: results from a prospective cohort study. European Respiratory Journal, 2017, 50, 1700094.	3.1	16
519	Chronic complications of venous thromboembolism. Journal of Thrombosis and Haemostasis, 2017, 15, 1531-1540.	1.9	48
520	Systemic Thrombolysis for Pulmonary Embolism: Who and How. Techniques in Vascular and Interventional Radiology, 2017, 20, 162-174.	0.4	13
521	Initiation of a Multidisciplinary, Rapid Response Team to Massive and Submassive Pulmonary Embolism. American Journal of Cardiology, 2017, 120, 1393-1398.	0.7	37
522	Risk of Thrombosis in Sjögren Syndrome: The Open Question of Endothelial Function Immune-mediated Dysregulation. Journal of Rheumatology, 2017, 44, 1106-1108.	1.0	4
523	The use of veno-venous extracorporeal membrane oxygenation following thrombolysis for massive pulmonary embolism. Journal of the Intensive Care Society, 2017, 18, 342-347.	1.1	2
524	Incidence of a single subsegmental mismatched perfusion defect in single-photon emission computed tomography and planar ventilation/perfusion scans. Nuclear Medicine Communications, 2017, 38, 135-140.	0.5	5
526	Management of intra-operative acute pulmonary embolism during general anesthesia: a case report. BMC Anesthesiology, 2017, 17, 67.	0.7	13
527	Does an 8-week home-based exercise program affect physical capacity, quality of life, sick leave, and use of psychotropic drugs in patients with pulmonary embolism? Study protocol for a multicenter randomized clinical trial. Trials, 2017, 18, 245.	0.7	6
528	Association of Traditional Cardiovascular Risk Factors With Venous Thromboembolism. Circulation, 2017, 135, 7-16.	1.6	114
529	YouTube as a potential source of information on deep venous thrombosis. Phlebology, 2017, 32, 543-547.	0.6	8
530	Evaluating the Potential of Routine Blood Tests to Identify the Risk of Deep Vein Thrombosis: A 1-Year Monocenter Cohort Study. Angiology, 2017, 68, 592-597.	0.8	6
532	Effects of walking in deep venous thrombosis: a new integrated solid and fluid mechanics model. International Journal for Numerical Methods in Biomedical Engineering, 2017, 33, e2819.	1.0	1
533	Start-up, Organization and Performance of a Multidisciplinary Pulmonary Embolism Response Team for the Diagnosis and Treatment of Acute Pulmonary Embolism. Revista Espanola De Cardiologia (English) Tj ETQq1	1 00 7 8431	4 ngBT /Over
534	Puesta en marcha, organización y rendimiento de un equipo multidisciplinario de respuesta a la embolia pulmonar para el diagnóstico y el tratamiento de la embolia pulmonar aguda. Revista Espanola De Cardiologia, 2017, 70, 9-13.	0.6	4
535	Clinical Prognosis of Nonmassive Central and Noncentral Pulmonary Embolism. Chest, 2017, 151, 829-837.	0.4	21
536	Incidence of Venous Thromboembolism in Asian Populations: A Systematic Review. Thrombosis and Haemostasis, 2017, 117, 2243-2260.	1.8	120
537	Progress in the research on venous thromboembolism. Current Medical Science, 2017, 37, 811-815.	0.7	7

ARTICLE IF CITATIONS # The management of acute venous thromboembolism in clinical practice. Thrombosis and Haemostasis, 538 1.8 74 2017, 117, 1326-1337. Ambulant treatment for a very elderly patient with acute deep vein thrombosis in a rural area: A case report. Journal of Rural Medicine: JRM, 2017, 12, 149-152. 0.2 New paradigms in venous thromboprophylaxis of medically ill patients. Thrombosis and Haemostasis, 540 1.8 44 2017, 117, 1662-1670. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. 541 1.8 193 Thrombosis and Haemostasis, 2017, 117, 57-65. Venous Thromboembolism in Liver Cirrhosis: An Emerging Issue., 2017,,. 542 1 Incidence and causes of venous thromboembolism recurrence in sub-Saharan Africa. Sang Thrombose 0.1 Vaisseaux, 2017, 29, 195-202. Intermittent Pneumatic Compression for the Prevention of Venous Thromboembolism after Total Hip 544 0.8 12 Arthroplasty. Clinics in Orthopedic Surgery, 2017, 9, 37. Recent Progress in Research on the Pathogenesis of Pulmonary Thromboembolism: An Old Story with New Perspectives. BioMed Research International, 2017, 2017, 1-10. Deep venous thrombosis among diabetic patients in King Abdulaziz University (KAU) Hospital, Jeddah, Kingdom of Saudi Arabia. Electronic Physician, 2017, 9, 5185-5190. 546 0.2 1 The safety of low-molecular-weight heparins in the prevention of venous thromboembolism in 547 surgically-treated cancer patients: results of a multicentre observational study. Wspolczesna Onkologia, 2017, 2, 152-156. Pulmonary embolism: epidemiological data and diagnosis in Kinshasa hospitals. International Journal 548 0.6 8 of Tuberculosis and Lung Disease, 2017, 21, 875-879. Influence of aspirin on the CX3CL1/CX3CR1 signaling pathway in acute pulmonary embolism. International Journal of Molecular Medicine, 2017, 39, 1580-1588. 1.8 Deep vein thrombosis related to environment. Molecular Medicine Reports, 2017, 15, 3445-3448. 550 1.1 15 Interventional radiology treatment for pulmonary embolism. World Journal of Radiology, 2017, 9, 295. Machine Learning Algorithms Dramatically Improve the Accuracy and Time to Diagnosis of Pulmonary 552 0.1 0 Embolisms. Journal of Pulmonary & Respiratory Medicine, 2017, 07, . Statins as a preventative therapy for venous thromboembolism. Cardiovascular Diagnosis and Therapy, 2017, 7, S207-S218. Ageâ€adjusted Dâ€dimer cutâ€off leads to more efficient diagnosis of venous thromboembolism in the 554 emergency department: a comparison of four assays. Journal of Thrombosis and Haemostasis, 2018, 16, 1.9 35 866-875. Real-world incidence of cancer following a first unprovoked venous thrombosis: Results from the EPIGETBO study. Thrombosis Research, 2018, 164, 79-84.

#	Article	IF	CITATIONS
556	Dual inhibition of HY023016 based on binding properties of platelet membrane receptor subunit glycoprotein Ibα and thrombin exosites. European Journal of Pharmacology, 2018, 822, 51-58.	1.7	0
557	Submassive Pulmonary Embolism. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 588-598.	2.5	50
558	Clinical Policy: Critical Issues in the Evaluation andÂManagement of Adult Patients Presenting toÂthe Emergency Department With Suspected Acute Venous Thromboembolic Disease. Annals of Emergency Medicine, 2018, 71, e59-e109.	0.3	57
559	Polymorphisms in PARK2 and MRPL37 are associated with higher risk of recurrent venous thromboembolism in a sex-specific manner. Journal of Thrombosis and Thrombolysis, 2018, 46, 154-165.	1.0	5
560	Risk Factors for Venous Thromboembolism in Hospitalized Patients in the Chinese Population. Open Life Sciences, 2018, 13, 82-89.	0.6	3
561	Asian patients versus non-Asian patients in the efficacy and safety of direct oral anticoagulants relative to vitamin K antagonist for venous thromboembolism: A systemic review and meta-analysis. Thrombosis Research, 2018, 166, 37-42.	0.8	18
562	State of play and future direction with NOACs: An expert consensus. Vascular Pharmacology, 2018, 106, 9-21.	1.0	9
563	Pulmonary Embolism in Focus. Hamostaseologie, 2018, 38, 07-08.	0.9	0
564	Pulmonary infarction secondary to pulmonary embolism: An evolving paradigm. Respirology, 2018, 23, 866-872.	1.3	25
565	Pulmonary embolism in Europe - Burden of illness in relationship to healthcare resource utilization and return to work. Thrombosis Research, 2018, 170, 181-191.	0.8	29
566	Venous thromboembolism controversies. Disease-a-Month, 2018, 64, 408-444.	0.4	3
567	Inverse association between serum albumin and future risk of venous thromboembolism: interrelationship with high sensitivity C-reactive protein. Annals of Medicine, 2018, 50, 240-248.	1.5	23
568	Recognition of unprovoked (idiopathic) pulmonary embolism–Prospective observational study. Respiratory Medicine, 2018, 135, 57-61.	1.3	11
569	Acute Pulmonary Embolism in a National Danish Cohort: Increasing Incidence and Decreasing Mortality. Thrombosis and Haemostasis, 2018, 118, 539-546.	1.8	81
570	Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association. Circulation, 2018, 137, e67-e492.	1.6	5,228
571	What have we learned from real-world NOAC studies in venous thromboembolism treatment?. Thrombosis Research, 2018, 163, 83-91.	0.8	22
572	Investigation of adverse events associated with an off-label use of arterial stents and CE-marked iliac vein stents in the iliac vein: insights into developing a better iliac vein stent. Journal of Artificial Organs, 2018, 21, 254-260.	0.4	9
573	Management of heavy menstrual bleeding during direct oral anticoagulant therapy for recurrent venous thromboembolism. Blood Coagulation and Fibrinolysis, 2018, 29, 391-394.	0.5	3

	CHATION	LEPUKI	
#	Article	IF	Citations
575	Pulmonary embolism: Care standards in 2018. Progress in Cardiovascular Diseases, 2018, 60, 613-621.	1.6	12
577	Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. American Heart Journal, 2018, 198, 84-90.	1.2	19
578	Rationale, Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE). Thrombosis and Haemostasis, 2018, 118, 214-224.	1.8	160
580	Incidence, Characteristics and Management of Venous Thromboembolism in Japan During 2011. Circulation Journal, 2018, 82, 555-560.	0.7	23
581	Direct oral anticoagulant use in patients with thrombophilia, antiphospholipid syndrome or venous thrombosis of unusual sites: A narrative review. Blood Reviews, 2018, 32, 272-279.	2.8	17
582	Are new anticoagulants a safe and reasonable alternative to low molecular heparins?. Thrombosis Research, 2018, 164, S157-S161.	0.8	3
583	Anticoagulation Therapy for Venous Thromboembolism in the Real World ― From the COMMAND VTE Registry ―. Circulation Journal, 2018, 82, 1262-1270.	0.7	105
584	Multimodality Assessment of Right Ventricular Strain in Patients With Acute Pulmonary Embolism. American Journal of Cardiology, 2018, 122, 175-181.	0.7	24
585	Pulmonary Embolism. Surgical Clinics of North America, 2018, 98, 279-292.	0.5	14
586	Diagnostic value of QRS and S wave variation in patients with suspicion of acute pulmonary embolism. American Journal of Emergency Medicine, 2018, 36, 2197-2202.	0.7	6
587	Venous Thromboembolism Quality Measures Fail to Accurately Measure Quality. Circulation, 2018, 137, 1278-1284.	1.6	45
588	Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies. Thrombosis and Haemostasis, 2018, 118, S23-S33.	1.8	12
589	Knowledge and practices of nurses on deep vein thrombosis risks and prophylaxis: A descriptive cross sectional study. Journal of Vascular Nursing, 2018, 36, 71-80.	0.2	24
590	Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis. Climacteric, 2018, 21, 341-345.	1.1	42
591	Risk factors for recurrence in deep vein thrombosis patients following a tailored anticoagulant treatment incorporating residual vein obstruction. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 299-309.	1.0	18
592	The Evaluation of Fibrin-Related Markers for Diagnosing or Predicting Acute or Subclinical Venous Thromboembolism in Patients Undergoing Major Orthopedic Surgery. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 107-114.	0.7	11
593	The Evaluation of D-Dimer Levels for the Comparison of Fibrinogen and Fibrin Units Using Different D-Dimer Kits to Diagnose VTE. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 655-662.	0.7	11
594	Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis. Phlebology, 2018, 33, 53-59.	0.6	7

#	Article	IF	CITATIONS
595	Comparison of Direct Iliofemoral Stenting Following AngioJet Rheolytic Thrombectomy vs Staged Stenting After AngioJet Rheolytic Thrombectomy Plus Catheter-Directed Thrombolysis in Patients With Acute Deep Vein Thrombosis. Journal of Endovascular Therapy, 2018, 25, 133-139.	0.8	24
596	Neuromuscular electrical stimulation for the prevention of venous thromboembolism. Phlebology, 2018, 33, 367-378.	0.6	18
597	Histological criteria for age determination of fatal venous thromboembolism. International Journal of Legal Medicine, 2018, 132, 775-780.	1.2	8
598	Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. Circulation, 2018, 137, 684-692.	1.6	22
599	Definition of indicators of the appropriateness of oral anticoagulant prescriptions in hospitalized adults: Literature review and consensus (PACHA study). Archives of Cardiovascular Diseases, 2018, 111, 155-171.	0.7	1
600	Lung function, functional capacity, and respiratory symptoms at discharge from hospital in patients with acute pulmonary embolism: A cross-sectional study. Physiotherapy Theory and Practice, 2018, 34, 194-201.	0.6	13
601	Approaches to prevent bleeding associated with anticoagulants: current status and recent developments. Drug Delivery and Translational Research, 2018, 8, 928-944.	3.0	18
602	Apixaban for the treatment of cancer-associated venous thromboembolism and left atrial appendage thrombus refractory to optimal anticoagulation with warfarin: a case report. European Heart Journal - Case Reports, 2018, 2, yty135.	0.3	1
603	Key topics in pulmonary vascular diseases (assembly 13) from the European Respiratory Society 2018 Parisian Congress. Journal of Thoracic Disease, 2018, 10, S3029-S3033.	0.6	1
604	Tissue perfusion alterations correlate with mortality in patients admitted to the intensive care unit for acute pulmonary embolism. Medicine (United States), 2018, 97, e11993.	0.4	5
605	Nephrotic syndrome with acute pulmonary embolism in young adults. Medicine (United States), 2018, 97, e11495.	0.4	9
606	THE FIBRINOLYTIC ALTERATION ASSOCIATED WITH DAILY ADMINISTRATION OF SILDENAFIL. Asian Journal of Pharmaceutical and Clinical Research, 2018, 11, 107.	0.3	0
608	Double Emergency Associating Acute Aortic Dissection and Pulmonary Embolism of Fatal Evolution: About a Case. Journal of Clinical & Experimental Cardiology, 2018, 9, .	0.0	2
609	Clinical and paraclinical patterns of presentation, and sensitivity of diagnostic scores for pulmonary embolism at the emergencies: retrospective study on the impact of age at the University hospitals of Strasbourg (France). Psychologie & Neuropsychiatrie Du Vieillissement, 2018, 16, 349-358.	0.2	0
610	Short- and long-term outcomes for the surgical treatment of acute pulmonary embolism. Innovative Surgical Sciences, 2018, 3, 271-276.	0.4	5
611	Pulmonary Embolism Response Teams: A Novel Approach for the Care of Complex Patients With Pulmonary Embolism. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 48S-55S.	0.7	20
612	Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. Thrombosis and Haemostasis, 2018, 118, 2046-2052.	1.8	48
613	Retrospective validation of a new volumetric capnography parameter for the exclusion of pulmonary embolism at the emergency department. ERJ Open Research, 2018, 4, 00099-2018.	1.1	5

#	Article	IF	CITATIONS
615	Acute Pulmonary Embolism. Journal of Radiology Nursing, 2018, 37, 222-225.	0.2	1
616	Determining the minimal clinically important difference for the PEmbQoL questionnaire, a measure of pulmonary embolismâ€specific quality of life. Journal of Thrombosis and Haemostasis, 2018, 16, 2454-2461.	1.9	19
617	Automated versus Manual Data Extraction of the Padua Prediction Score for Venous Thromboembolism Risk in Hospitalized Older Adults. Applied Clinical Informatics, 2018, 09, 743-751.	0.8	5
618	Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism. Expert Review of Cardiovascular Therapy, 2018, 16, 845-855.	0.6	5
619	Rivaroxaban or vitamin-K antagonists following early endovascular thrombus removal and stent placement for acute iliofemoral deep vein thrombosis. Thrombosis Research, 2018, 172, 86-93.	0.8	25
620	When appearances deceive: Echocardiographic changes due to common chest pathology. Echocardiography, 2018, 35, 1847-1859.	0.3	1
621	The impact of co-morbidity on the disease burden of VTE. Journal of Thrombosis and Thrombolysis, 2018, 46, 507-515.	1.0	9
622	Influence of Baseline Platelet Count on Outcomes in Patients With Venous Thromboembolism (from) Tj ETQq1 1	0.784314	rgBT /Overld
623	Diagnosis of pulmonary embolism: should we wait <scp>YEARS</scp> ?. British Journal of Haematology, 2018, 183, 165-167.	1.2	0
624	Venous thromboembolism risk associated with ABO, F11 and FGG loci. Blood Coagulation and Fibrinolysis, 2018, 29, 528-532.	0.5	6
625	The endothelial tumor suppressor p53 is essential for venous thrombus formation in aged mice. Blood Advances, 2018, 2, 1300-1314.	2.5	16
626	Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood Advances, 2018, 2, 788-796.	2.5	71
628	The secondary prevention of venous thromboembolism: Towards an individual therapeutic strategy. Vascular, 2018, 26, 670-682.	0.4	3
629	Gender Differences Among Patients With Acute Pulmonary Embolism. American Journal of Cardiology, 2018, 122, 1079-1084.	0.7	23
630	Just How Attractive is the ATTRACT Trial?. CardioVascular and Interventional Radiology, 2018, 41, 1313-1317.	0.9	19
631	Thromboembolism prophylaxis in orthopaedics: an update. EFORT Open Reviews, 2018, 3, 136-148.	1.8	142
632	Reperfusion in acute pulmonary thromboembolism. Jornal Brasileiro De Pneumologia, 2018, 44, 237-243.	0.4	9
633	Home treatment of acute pulmonary embolism. Current Opinion in Pulmonary Medicine, 2018, 24, 425-431.	1.2	17

#	Article	IF	CITATIONS
634	Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK. Journal of Market Access & Health Policy, 2018, 6, 1495974.	0.8	4
635	Cooperative PSGL-1 and CXCR2 signaling in neutrophils promotes deep vein thrombosis in mice. Blood, 2018, 132, 1426-1437.	0.6	80
636	Cytokines, Adhesion Molecules, and Matrix Metalloproteases as Predisposing, Diagnostic, and Prognostic Factors in Venous Thrombosis. Frontiers in Medicine, 2018, 5, 147.	1.2	42
638	Depression, antidepressant use, and risk of venous thromboembolism: systematic review and meta-analysis of published observational evidence. Annals of Medicine, 2018, 50, 529-537.	1.5	31
639	Acute Pulmonary Embolism: Focus on the Clinical Picture. Korean Circulation Journal, 2018, 48, 365.	0.7	74
640	Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. Thrombosis Research, 2018, 168, 121-129.	0.8	11
641	Reducing the burden of venous thromboembolism in the acute medically ill population with extended-duration thromboprophylaxis. European Heart Journal Supplements, 2018, 20, E6-E11.	0.0	4
643	The diagnosis and treatment of venous thromboembolism in Asian patients. Thrombosis Journal, 2018, 16, 4.	0.9	65
645	Extended thromboprophylaxis with betrixaban: a new standard for acute medically ill patients. European Heart Journal Supplements, 2018, 20, E1-E2.	0.0	8
646	Pharmacological properties of betrixaban. European Heart Journal Supplements, 2018, 20, E12-E15.	0.0	32
647	Betrixaban for prevention of venous thromboembolism in acute medically ill patients. European Heart Journal Supplements, 2018, 20, E16-E22.	0.0	7
648	Deep-vein thrombosis in Europe — Burden of illness in relationship to healthcare resource utilization and return to work. Thrombosis Research, 2018, 170, 165-174.	0.8	14
649	Treatment of high- and intermediate-risk pulmonary embolism using the AngioJet percutaneous mechanical thrombectomy system in patients with contraindications for thrombolytic treatment – a pilot study. Wideochirurgia I Inne Techniki Maloinwazyjne, 2018, 13, 233-242.	0.3	8
650	Postoperative major surgery patients developing silent deep vein thrombosis: A prospective observational study. Journal of Vascular Nursing, 2018, 36, 173-180.	0.2	2
651	DVT Intervention in the Post-ATTRACT Era. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 70.	0.4	7
652	Pulmonary Thromboembolism. , 2018, , 429-434.		0
653	Glycoprotein IIb/IIIa Receptor Imaging with ¹⁸ F-GP1 PET for Acute Venous Thromboembolism: An Open-Label, Nonrandomized, Phase 1 Study. Journal of Nuclear Medicine, 2019, 60, 244-249.	2.8	27
654	Early decisionâ€making in acute pulmonary embolism: a retrospective clinical audit. Internal Medicine Journal, 2019, 49, 481-489.	0.5	1

#	Article	IF	Citations
655	Transcutaneous carbon dioxide monitoring as a predictive tool for all-cause 6-month mortality after acute pulmonary embolism. European Journal of Internal Medicine, 2019, 68, 44-50.	1.0	1
656	EANM guideline for ventilation/perfusion single-photon emission computed tomography (SPECT) for diagnosis of pulmonary embolism and beyond. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2429-2451.	3.3	130
657	Microbubble Enhanced Ultrasound-Assisted Catheter-Directed Thrombolysis for VTE—A Sound Idea?. Thrombosis and Haemostasis, 2019, 119, 1036-1036.	1.8	0
658	Comparison among different presentations of venous thromboembolism because of lung cancer. Clinical Respiratory Journal, 2019, 13, 574-582.	0.6	8
659	The stimulation of thrombosis by hypoxia. Thrombosis Research, 2019, 181, 77-83.	0.8	316
660	Thrombolysis with tissue plasminogen activator in patients with acute pulmonary embolisms in the real world: from the COMMAND VTE registry. Journal of Thrombosis and Thrombolysis, 2019, 48, 587-595.	1.0	6
661	Cost of Healthcare Associated With Deep Vein Thrombosis in Patients Treated With Warfarin in Turkey: 2010-2013 Database Analysis of a Tertiary Care Center. Value in Health Regional Issues, 2019, 19, 81-86.	0.5	2
662	Elevated Complement C3 and C4 Levels are Associated with Postnatal Pregnancy-Related Venous Thrombosis. Thrombosis and Haemostasis, 2019, 119, 1481-1488.	1.8	4
663	Abdominal visceral adipose tissue is associated with unsuspected pulmonary embolism on routine CT scans in patients with gastrointestinal cancer. British Journal of Radiology, 2019, 92, 20190526.	1.0	2
664	Comparison of the Efficacy and Safety of Aspirin and Rivaroxaban Following Enoxaparin Treatment for Prevention of Venous Thromboembolism after Hip Fracture Surgery. Orthopaedic Surgery, 2019, 11, 886-894.	0.7	12
665	Clinical outcomes of patients with pulmonary embolism versus deep vein thrombosis: From the COMMAND VTE Registry. Thrombosis Research, 2019, 184, 50-57.	0.8	13
666	Survival Benefit of Obese Patients With Pulmonary Embolism. Mayo Clinic Proceedings, 2019, 94, 1960-1973.	1.4	30
667	Cost-effectiveness of rivaroxaban versus apixaban for the initial treatment of venous thromboembolism and extended prevention of recurrences in the UK. Journal of Medical Economics, 2019, 22, 1179-1191.	1.0	3
669	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Respiratory Journal, 2019, 54, 1901647.	3.1	806
670	Clinical Characteristics and Outcomes of Venous Thromboembolisms According to an Out-of-Hospital vs. In-Hospital Onset ― From the COMMAND VTE Registry ―. Circulation Journal, 2019, 83, 1377-1384.	0.7	7
671	Risk adapted management of acute pulmonary embolism in women. Thrombosis Research, 2019, 181, S29-S32.	0.8	3
672	Differences in Clinical Presentation, Rate of Pulmonary Embolism, and Risk Factors Among Patients With Deep Vein Thrombosis in Unusual Sites. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961987255.	0.7	5
673	Optimizing the Personalized, Risk-Adjusted Management of Pulmonary Embolism: An Integrated Clinical Trial Programme. Hamostaseologie, 2019, 39, 117-127.	0.9	4

	CHANON		
#	Article	IF	CITATIONS
674	A largeâ€scale exome array analysis of venous thromboembolism. Genetic Epidemiology, 2019, 43, 449-457.	0.6	22
675	Prevalence, symptom burden, and natural history of deep vein thrombosis in people with advanced cancer in specialist palliative care units (HIDDen): a prospective longitudinal observational study. Lancet Haematology,the, 2019, 6, e79-e88.	2.2	54
676	Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association. Circulation, 2019, 139, e56-e528.	1.6	6,192
677	Venous thromboembolism incidence in the Ireland east hospital group: a retrospective 22-month observational study. BMJ Open, 2019, 9, e030059.	0.8	2
678	Coping with everyday life and physical activity in the aftermath of an acute pulmonary embolism: A qualitative study exploring patients' perceptions and coping strategies. Thrombosis Research, 2019, 182, 185-191.	0.8	29
679	Improving fibrinolysis in venous thromboembolism: impact of fibrin structure. Expert Review of Hematology, 2019, 12, 597-607.	1.0	12
680	Thrombolysis in high-risk patients with acute pulmonary embolism: underuse of a life-saving treatment in the real-world setting. European Heart Journal, 2020, 41, 530-533.	1.0	5
681	Sex Differences in Clinical Characteristics and Outcomes of Patients With Venous Thromboembolism ― From the COMMAND VTE Registry ―. Circulation Journal, 2019, 83, 1581-1589.	0.7	14
682	Venous Thromboembolism as an Adverse Effect During Treatment With Olanzapine: A Case Series. Frontiers in Psychiatry, 2019, 10, 330.	1.3	10
683	Cardiorespiratory fitness is not associated with risk of venous thromboembolism: a cohort study. Scandinavian Cardiovascular Journal, 2019, 53, 255-258.	0.4	17
684	Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany. European Heart Journal, 2020, 41, 522-529.	1.0	259
685	A clinical predictive model for postâ€hospitalisation venous thromboembolism in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2019, 49, 1493-1501.	1.9	31
686	Safety and Effectiveness of Edoxaban in Japanese Patients With Venous Thromboembolism ― An Interim Analysis of Data From a Japanese Postmarketing Observational Study (ETNA-VTE-Japan) ―. Circulation Journal, 2019, 83, 1394-1404.	0.7	7
687	Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2019, 48, 439-453.	1.0	20
688	Respiratory rate and pulmonary embolus. QJM - Monthly Journal of the Association of Physicians, 2020, 113, 144-145.	0.2	0
689	Fatal Massive Pulmonary Embolism Following a Minor Ankle Injury as a Rare Cause of Sudden Unexpected Death: A Case Report. Journal of Foot and Ankle Surgery, 2019, 58, 792-794.	0.5	2
690	Thromboembolism and Bleeding. , 2019, , 1297-1316.		0
691	Lipoprotein(a) is not associated with venous thromboembolism risk. Scandinavian Cardiovascular Journal, 2019, 53, 125-132.	0.4	7
			-

ATION P

#	Article	IF	CITATIONS
692	D-dimer value in the diagnosis of pulmonary embolism—may it exclude only?. Journal of Thoracic Disease, 2019, 11, 664-672.	0.6	17
693	Physical activity and risk of recurrence and mortality after incident venous thromboembolism. Journal of Thrombosis and Haemostasis, 2019, 17, 901-911.	1.9	4
694	The case for extended thromboprophylaxis in medically hospitalised patients – not yet made. European Journal of Preventive Cardiology, 2019, , 204748731983657.	0.8	2
695	Reversal of Novel Anticoagulants in Emergent Surgery and Trauma: A Comprehensive Review and Proposed Management Algorithm. Current Pharmaceutical Design, 2019, 24, 4540-4553.	0.9	15
696	Deep vein thrombosis in upper extremities: Clinical characteristics, management strategies and long-term outcomes from the COMMAND VTE Registry. Thrombosis Research, 2019, 177, 1-9.	0.8	24
697	Second-Order Peer Reviews of Clinically Relevant Articles for the Physiatrist. American Journal of Physical Medicine and Rehabilitation, 2019, 98, e40-e42.	0.7	0
698	Reducing the hospital burden associated with the treatment of pulmonary embolism. Journal of Thrombosis and Haemostasis, 2019, 17, 720-736.	1.9	29
699	Overdiagnosis of pulmonary embolism: definition, causes and implications. Breathe, 2019, 15, 46-53.	0.6	29
700	Proximal and isolated distal deep vein thrombosis and Wells score accuracy in hospitalized patients. Internal and Emergency Medicine, 2019, 14, 941-947.	1.0	17
701	Health-related quality of life and mortality in patients with pulmonary embolism: a prospective cohort study in seven European countries. Quality of Life Research, 2019, 28, 2111-2124.	1.5	38
702	Influence of baseline anemia on long-term clinical outcomes in patients with venous thromboembolism: from the COMMAND VTE registry. Journal of Thrombosis and Thrombolysis, 2019, 47, 444-453.	1.0	7
703	Anticoagulant and Antiplatelet Therapy. , 2019, , 870-894.		3
704	Rivaroxaban for prevention and treatment of venous thromboembolism. Future Cardiology, 2019, 15, 63-77.	0.5	7
705	Thromboprophylaxis for varicose vein procedures – A national survey. Phlebology, 2019, 34, 598-603.	0.6	13
706	General practitioner use of D-dimer in suspected venous thromboembolism: historical cohort study in one geographical region in the Netherlands. BMJ Open, 2019, 9, e026846.	0.8	5
707	Potential of Multidimensional, Large-scale Biodatabases to Elucidate Coagulation and Platelet Pathways as an Approach towards Precision Medicine in Thrombotic Disease. Hamostaseologie, 2019, 39, 152-163.	0.9	8
708	10 Fall 10: Pulslosigkeit nach Wirbelsälenoperation. , 2019, , .		0
709	Long-term Impact of Bariatric Surgery on Venous Thromboembolic Risk. Annals of Surgery, 2019, Publish Ahead of Print, 1017-1024.	2.1	8

#	Article	IF	CITATIONS
710	Deep Vein Thrombosis in Europe—Health-Related Quality of Life and Mortality. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961988394.	0.7	26
711	Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961988602.	0.7	51
712	Rationale for catheter-based therapies in acute pulmonary embolism. European Heart Journal Supplements, 2019, 21, 116-122.	0.0	12
713	Future perspectives in catheter-based treatment of pulmonary embolism. European Heart Journal Supplements, 2019, 21, I31-I37.	0.0	5
714	Pulmonary embolism with abdominal pain as the chief complaint. Medicine (United States), 2019, 98, e17791.	0.4	5
715	A novel ECG parameter for diagnosis of acute pulmonary embolism: RS time. American Journal of Emergency Medicine, 2019, 37, 1230-1236.	0.7	11
716	Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. Thrombosis and Haemostasis, 2019, 119, 319-327.	1.8	76
717	A multidisciplinary pulmonary embolism response team (PERT)—experience from a national multicenter consortium. Pulmonary Circulation, 2019, 9, 1-10.	0.8	45
718	Faster fibrin clot degradation characterizes patients with central pulmonary embolism at a low risk of recurrent peripheral embolism. Scientific Reports, 2019, 9, 72.	1.6	15
719	Right Heart Thrombi: Patient Outcomes by Treatment Modality and Predictors of Mortality: A Pooled Analysis. Journal of Intensive Care Medicine, 2019, 34, 930-937.	1.3	15
720	Acute pulmonary embolism: a concise review of diagnosis and management. Internal Medicine Journal, 2019, 49, 15-27.	0.5	57
721	Venous Thromboembolism Prophylaxis in Neurocritical Care Patients: Are Current Practices, Best Practices?. Neurocritical Care, 2019, 30, 355-363.	1.2	18
722	Incidence, mortality and bleeding rates associated with pulmonary embolism in England between 1997 and 2015. International Journal of Cardiology, 2019, 277, 229-234.	0.8	25
723	Clinical decision support system for venous thromboembolism risk classification. Applied Computing and Informatics, 2019, 15, 12-18.	3.7	15
724	Venous stent patency may be affected by collateral vein lumen size. Phlebology, 2019, 34, 32-39.	0.6	3
725	Validation of simplified PESI score for identification of low-risk patients with pulmonary embolism: From the COMMAND VTE Registry. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 262-270.	0.4	36
726	Budget impact analysis of betrixaban for venous thromboembolism prophylaxis in nonsurgical patients with acute medical illness in the United Kingdom. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 259-267.	0.7	1
727	Pathologic up-regulation of TNFSF15–TNFRSF25 axis sustains endothelial dysfunction in unprovoked venous thromboembolism. Cardiovascular Research, 2020, 116, 698-707.	1.8	8

#	Article	IF	CITATIONS
728	Obstructive sleep apnea is associated with worse clinicalâ€radiological risk scores of pulmonary embolism. Journal of Sleep Research, 2020, 29, e12871.	1.7	12
729	Acute Pulmonary Embolism: Imaging Techniques, Findings, Endovascular Treatment and Differential Diagnoses. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2020, 192, 38-49.	0.7	19
730	Trends in mortality related to pulmonary embolism in the European Region, 2000–15: analysis of vital registration data from the WHO Mortality Database. Lancet Respiratory Medicine,the, 2020, 8, 277-287.	5.2	192
731	Usefulness of Simplified Pulmonary Embolism Severity Index Score for Identification of Patients With Low-Risk Pulmonary Embolism and Active Cancer. Chest, 2020, 157, 636-644.	0.4	25
732	Clinical ultrasonography in venous thromboembolism disease. Revista Clínica Espanõla, 2020, 220, 126-134.	0.3	2
733	Professional liability and patient safety in thromboembolic disease. Phlebology, 2020, 35, 184-189.	0.6	0
734	Extended duration of thromboprophylaxis for medically ill patients: a systematic review and metaâ€analysis of randomised controlled trials. Internal Medicine Journal, 2020, 50, 192-199.	0.5	19
735	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal, 2020, 41, 543-603.	1.0	2,426
736	Right ventricular strain in patients with pulmonary embolism and syncope. Journal of Thrombosis and Thrombolysis, 2020, 50, 157-164.	1.0	14
737	A randomised controlled trial of extended anticoagulation treatment <i>versus</i> standard treatment for the prevention of recurrent venous thromboembolism (VTE) and postâ€thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (the ExACT study). British lournal of Haematology, 2020, 188, 962-975.	1.2	22
738	Host-related factors for venous thromboembolism following total joint replacement: A meta-analysis of 89 observational studies involving over 14 million hip and knee replacements. Journal of Orthopaedic Science, 2020, 25, 267-275.	0.5	9
739	Temporal Trends in the Practice Pattern for Venous Thromboembolism in Japan: Insight From JROADâ€DPC. Journal of the American Heart Association, 2020, 9, e014582.	1.6	33
740	Randomized Trial of Deep Vein Thrombosis Chemoprophylaxis with Bemiparin and Enoxaparin in Patients with Moderate to High Thrombogenic Risk Undergoing Plastic and Reconstructive Surgery Procedures. Aesthetic Plastic Surgery, 2020, 44, 820-829.	0.5	4
741	Acute Perioperative Pulmonary Embolism—Management Strategies and Outcomes. Journal of Cardiothoracic and Vascular Anesthesia, 2020, 34, 1972-1984.	0.6	6
742	Broadening the Categories of Patients Eligible for Extended Venous Thromboembolism Treatment. Thrombosis and Haemostasis, 2020, 120, 014-026.	1.8	16
743	Association between venous thromboembolism and acute pancreatitis: An analysis from the nationwide inpatient sample. Clinical Respiratory Journal, 2020, 14, 320-327.	0.6	6
744	Physical activity and risk of venous thromboembolism: systematic review and meta-analysis of prospective cohort studies. European Journal of Epidemiology, 2020, 35, 431-442.	2.5	56
745	Risk and protective factors for post-thrombotic syndrome after deep venous thrombosis. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2020, 8, 390-395.	0.9	12

#	Article	IF	CITATIONS
746	Does cell-free DNA promote coagulation and inhibit fibrinolysis in patients with unprovoked venous thromboembolism?. Thrombosis Research, 2020, 186, 13-19.	0.8	11
747	Extracorporeal Membrane Oxygenation for Massive Pulmonary Embolism as Bridge to Therapy. ASAIO Journal, 2020, 66, 146-152.	0.9	31
748	Developing patient information and clinician education resources for venous thromboembolism in a physiotherapy department in response to the COVID-19 pandemic. International Journal of Therapy and Rehabilitation, 2020, 27, 1-7.	0.1	0
749	Significant increase in the incidence of high-risk pulmonary embolism during the COVID-19 shutdown: The pandemic response causes serious collateral consequences. European Journal of Internal Medicine, 2020, 82, 120-122.	1.0	3
750	Multiple comparisons of the efficacy and safety for six treatments in Acute Achilles Tendon Rupture patients: A systematic review and network meta-analysis. Foot and Ankle Surgery, 2020, 27, 468-479.	0.8	13
751	Effect of enoxaparin on plasma fibrin clot properties and fibrin structure in patients with acute pulmonary embolism. Vascular Pharmacology, 2020, 133-134, 106783.	1.0	7
752	Investigation of pulmonary embolism in patients with chest pain in the emergency department: a retrospective multicenter study. European Journal of Emergency Medicine, 2020, 27, 357-361.	0.5	5
753	Impact of ED Organization with a Holding Area and a Dedicated Team on the Adherence to International Guidelines for Patients with Acute Pulmonary Embolism: Experience of an Emergency Department Organized in Areas of Intensity of Care. Medicines (Basel, Switzerland), 2020, 7, 60.	0.7	16
754	Frequency of thrombophilia associated genes variants: population-based study. BMC Medical Genetics, 2020, 21, 198.	2.1	3
755	Tratamiento domiciliario de la enfermedad tromboembólica venosa. Revista Clinica Espanola, 2020, 220, 78-85.	0.2	0
756	Massive pulmonary embolism with intra-hospital cardiac arrest and full recovery of right ventricular function after veno-arterial extracorporeal membrane oxygenation therapy: a case report. European Heart Journal - Case Reports, 2020, 4, 1-6.	0.3	2
757	Handgrip strength is not associated with risk of venous thromboembolism: a prospective cohort study. Scandinavian Cardiovascular Journal, 2020, 54, 253-257.	0.4	10
758	Association between congenital thrombophilia and outcomes in pulmonary embolism patients. Blood Advances, 2020, 4, 5958-5965.	2.5	18
759	The role of bone marrow-derived cells in venous thromboembolism. International Journal of Biochemistry and Cell Biology, 2020, 128, 105850.	1.2	6
760	Inferior Vena Cava Filters. Chest, 2020, 158, 2579-2589.	0.4	33
761	Green synthesized novel silver nanoparticles and their application as anticoagulant and thrombolytic agents: A perspective. IOP Conference Series: Materials Science and Engineering, 2020, 805, 012043.	0.3	14
762	Plasma catestatin level predicts sPESI score and mortality in acute pulmonary embolism. Archives of Medical Sciences Atherosclerotic Diseases, 2020, 5, 49-56.	0.5	5
763	Inpatient prophylaxis in cancer patients: where is the evidence?. Thrombosis Research, 2020, 191, S85-S90.	0.8	3

#	Article	IF	CITATIONS
764	Prevention of Venous Thromboembolism in 2020 and Beyond. Journal of Clinical Medicine, 2020, 9, 2467.	1.0	82
765	Impact of concomitant deep or superficial venous thrombosis of the legs on survival of patients with pulmonary embolism. International Journal of Cardiology, 2020, 315, 92-98.	0.8	11
766	Impact of Patient Characteristics on Treatment Outcomes in Symptomatic Venous Thromboembolism: Results of HOKUSAI-VTE Randomized Trial Analysis. TH Open, 2020, 04, e245-e254.	0.7	0
767	Perspectives of patients and health professionals on important factors influencing rehabilitation following acute pulmonary embolism: A multi-method study. Thrombosis Research, 2020, 196, 283-290.	0.8	3
768	Highâ€risk pulmonary embolism with outâ€ofâ€hospital cardiac arrest: Acute multidisciplinary approach leading to surgical embolectomy with good clinical outcome. Clinical Case Reports (discontinued), 2020, 8, 2753-2758.	0.2	1
770	Definition of tachycardia for risk stratification of pulmonary embolism. European Journal of Internal Medicine, 2020, 82, 76-82.	1.0	12
771	Evaluation of stability of deep venous thrombosis of the lower extremities using Doppler ultrasound. Journal of International Medical Research, 2020, 48, 030006052094209.	0.4	1
772	Systematic review and meta-analysis of test accuracy for the diagnosis of suspected pulmonary embolism. Blood Advances, 2020, 4, 4296-4311.	2.5	39
773	<p>Microbial Modulation of Coagulation Disorders in Venous Thromboembolism</p> . Journal of Inflammation Research, 2020, Volume 13, 387-400.	1.6	11
774	Prevalence of Venous Thromboembolism in Kumasi: A Postmortem-Based Study in a Tertiary Hospital in Ghana. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2020, 14, 117954842095636.	0.5	1
775	Clinical outcomes of acute pulmonary embolectomy as the first-line treatment for massive and submassive pulmonary embolism: a single-centre study in China. Journal of Cardiothoracic Surgery, 2020, 15, 321.	0.4	11
776	Predictors of Poor Quality of Life after Primary Lower Limb Deep Venous Thrombosis: A Perspective from a Developing Nation. Annals of Vascular Diseases, 2020, 13, 63-68.	0.2	3
777	The lived experience with pulmonary embolism: A qualitative study using focus groups. Respiratory Medicine, 2020, 167, 105978.	1.3	21
778	Pulmonary Embolism. Heart Failure Clinics, 2020, 16, 317-330.	1.0	9
779	Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial. Blood Advances, 2020, 4, 2254-2260.	2.5	22
780	Economic Evaluation of Rivaroxaban Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Knee Replacement and Total Hip Replacement: A Systematic Review. Clinical Drug Investigation, 2020, 40, 715-725.	1.1	10
781	Evaluation of the SAMe-TT2R2 score to predict the quality of anticoagulation control in patients with venous thromboembolism treated with vitamin K antagonists: Findings from the RIETE registry. Thrombosis Research, 2020, 194, 178-182.	0.8	3
782	Advances in the Diagnosis of Venous Thromboembolism: A Literature Review. Diagnostics, 2020, 10, 365.	1.3	19

#	Article	IF	CITATIONS
784	Physical activity and respiratory symptoms after pulmonary embolism. A longitudinal observational study. Thrombosis Research, 2020, 189, 55-60.	0.8	8
785	Impact of concomitant antiplatelet therapy on the efficacy and safety of direct oral anticoagulants for acute venous thromboembolism: Systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 1661-1671.	1.9	10
786	Hepatic venous Doppler assessment can anticipate simplified pulmonary embolism severity index and right ventricle dysfunction in patients with acute pulmonary embolism. Journal of Clinical Ultrasound, 2020, 48, 254-262.	0.4	2
787	Validation of risk assessment models predicting venous thromboembolism in acutely ill medical inpatients: A cohort study. Journal of Thrombosis and Haemostasis, 2020, 18, 1398-1407.	1.9	25
788	Association between risk stratification for pulmonary embolism and deep vein thrombosis of lower extremities. Clinical Respiratory Journal, 2020, 14, 631-637.	0.6	8
789	Pulmonary vasodilation in acute pulmonary embolism – a systematic review. Pulmonary Circulation, 2020, 10, 1-16.	0.8	31
791	Loop-mediated isothermal amplification (LAMP)-based method for detecting factor V Leiden and factor II G20210A common variants. Journal of Thrombosis and Thrombolysis, 2020, 50, 908-912.	1.0	3
792	Prevention of health care associated venous thromboembolism through implementing VTE prevention clinical practice guidelines in hospitalized medical patients: a systematic review and meta-analysis. Implementation Science, 2020, 15, 49.	2.5	10
793	The Incidence and Characteristics of Venous Thromboembolism in Neurocritical Care Patients: A Prospective Observational Study. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962090795.	0.7	9
794	Effect of a Physiotherapist-Guided Home-Based Exercise Intervention on Physical Capacity and Patient-Reported Outcomes Among Patients With Acute Pulmonary Embolism. JAMA Network Open, 2020, 3, e200064.	2.8	35
795	The prognostic value of the serum albumin level for longâ€ŧerm prognosis in patients with acute pulmonary embolism. Clinical Respiratory Journal, 2020, 14, 578-585.	0.6	13
796	Right Ventricular Early Inflowâ€Outflow Index—A new method for echocardiographic evaluation of right ventricle dysfunction in acute pulmonary embolism. Echocardiography, 2020, 37, 223-230.	0.3	5
797	Inappropriate Venous Thromboembolism Prophylaxis in a General Surgery Department: Risk Factors and Improvement with a Simple Educational Program. Indian Journal of Surgery, 2020, 82, 855-860.	0.2	1
798	Management of antithrombotic therapy in gray areas of venous thromboembolism: a Delphi consensus panel. Internal and Emergency Medicine, 2020, 15, 1255-1264.	1.0	0
799	Leisure-time cross-country skiing and the risk of venous thromboembolism: A prospective cohort study. European Journal of Preventive Cardiology, 2020, , 2047487320908978.	0.8	2
800	Epidemiology of Venous Thromboembolism After Second Cancer. Clinical Epidemiology, 2020, Volume 12, 377-386.	1.5	2
801	Changes in inferior vena cava filter placement and retrieval practice patterns from a population health perspective. Abdominal Radiology, 2020, 45, 3907-3914.	1.0	7
802	Variable predictors of acute pulmonary embolism recurrence with duration of follow-up. Journal of Thoracic Disease, 2020, 12, 403-413.	0.6	1

#	Article	IF	CITATIONS
803	Elevated Lactate Levels in Acute Pulmonary Embolism Are Associated with Prothrombotic Fibrin Clot Properties: Contribution of NETs Formation. Journal of Clinical Medicine, 2020, 9, 953.	1.0	22
804	New Paradigms of Extended Thromboprophylaxis in Medically Ill Patients. Journal of Clinical Medicine, 2020, 9, 1002.	1.0	12
805	Variations in incidence of venous thromboembolism in low-, middle-, and high-income countries. Cardiovascular Research, 2021, 117, 576-584.	1.8	31
806	Longâ€ŧerm outcomes in patients with pulmonary embolism: results from a longitudinal cohort study. Internal Medicine Journal, 2021, 51, 699-704.	0.5	1
807	Ethnoracial variations in venous thrombosis: Implications for management, and a call to action. Journal of Thrombosis and Haemostasis, 2021, 19, 30-40.	1.9	8
808	The echocardiographic ratio tricuspid annular plane systolic excursion/pulmonary arterial systolic pressure predicts short-term adverse outcomes in acute pulmonary embolism. European Heart Journal Cardiovascular Imaging, 2021, 22, 285-294.	0.5	40
809	Systematic review on the benefit of graduated compression stockings in the prevention of venous thromboembolism in low-risk surgical patients. Phlebology, 2021, 36, 184-193.	0.6	6
810	Impact of no, distal, and proximal deep vein thrombosis on clinical outcomes in patients with acute pulmonary embolism: From the COMMAND VTE registry. Journal of Cardiology, 2021, 77, 395-403.	0.8	5
811	Venous thromboembolism after lower extremity orthopedic surgery: A populationâ€based nationwide cohort study. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 148-158.	1.0	9
812	Rescue catheter-based therapies for the treatment of acute massive pulmonary embolism after unsuccessful systemic thrombolysis. Journal of Thrombosis and Thrombolysis, 2021, 51, 805-813.	1.0	5
814	Kardiopulmonale Reanimation bei Erwachsenen. , 2021, , 125-136.		0
815	Can we predict and prevent the postthrombotic syndrome?. Vasa - European Journal of Vascular Medicine, 2021, 50, 11-21.	0.6	4
816	Influence of lipid metabolism disorders on venous thrombosis risk. Journal of Medical Biochemistry, 2021, 40, 245-251.	0.7	6
818	Venoarterial Extracorporeal Membrane Oxygenation in Massive Pulmonary Embolism-Related Cardiac Arrest: A Systematic Review*. Critical Care Medicine, 2021, 49, 760-769.	0.4	30
819	Histopathologic analysis of extracted thrombi from deep venous thrombosis and pulmonary embolism: Mechanisms and timing. Catheterization and Cardiovascular Interventions, 2021, 97, 1422-1429.	0.7	14
820	Analysis of the Introduction in Clinical Practice of New Oral Anticoagulants in Local Health Agency BT: Translation of the Clinical Trial Data to a Local Health Care Area. Pharmaceutics, 2021, 13, 252.	2.0	2
822	Drug-induced liver injury associated with acenocumarol exposure. Drugs and Therapy Perspectives, 2021, 37, 120-123.	0.3	1
824	Midterm Prognosis of Patients With Pulmonary Embolism Receiving Catheterâ€Directed Thrombolysis or Systemic Thrombolysis: A Nationwide Populationâ€Based Study. Journal of the American Heart Association, 2021, 10, e019296.	1.6	3

#	Article	IF	CITATIONS
825	Prediction models for recurrence and bleeding in patients with venous thromboembolism: A systematic review and critical appraisal. Thrombosis Research, 2021, 199, 85-96.	0.8	25
826	Relevance of immobility as a risk factor for symptomatic proximal and isolated distal deep vein thrombosis in acutely ill medical inpatients. Vascular Medicine, 2021, 26, 542-548.	0.8	8
827	ANTITHROMBOTIC EFFECTS OF SULODEXIDE: A REVIEW ARTICLE., 2021,, 49-53.		0
828	The Neutrophil Secretome as a Crucial Link between Inflammation and Thrombosis. International Journal of Molecular Sciences, 2021, 22, 4170.	1.8	17
829	Short Duration Catheter-directed Thrombolysis for Acute Pulmonary Embolism Rapidly Improves Acute Cardiac Function. Annals of Vascular Surgery, 2021, 72, 373-382.	0.4	0
830	Massive pulmonary embolism presenting with hemoptysis and S1Q3T3 ECG findings. BMC Cardiovascular Disorders, 2021, 21, 224.	0.7	2
831	Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE. Thrombosis Research, 2021, 201, 63-72.	0.8	14
832	Deformation mechanics of self-expanding venous stents: Modelling and experiments. Journal of Biomechanics, 2021, 120, 110333.	0.9	7
833	The Effect of The Thrombolytic Treatment on Inflammatory Markers in Male Patients with Pulmonary Thromboembolism. Sakarya Medical Journal, 0, , .	0.1	0
834	Economic Evaluation of New Oral Anticoagulants in Prevention of Venous Thrombosis Following Joint Replacement Surgery: A Systematic Review. Clinical Therapeutics, 2021, 43, e139-e156.	1.1	8
835	Interplay between inflammation and thrombosis in cardiovascular pathology. Nature Reviews Cardiology, 2021, 18, 666-682.	6.1	337
836	Thrombosis: Grand Challenges Ahead!. Frontiers in Cardiovascular Medicine, 2021, 8, 637005.	1.1	1
837	STOP leg clots—Swedish multicentre trial of outpatient prevention of leg clots: study protocol for a randomised controlled trial on the efficacy of intermittent pneumatic compression on venous thromboembolism in lower leg immobilised patients. BMJ Open, 2021, 11, e044103.	0.8	1
838	Venous Thromboembolism Prophylaxis in Elective Neurosurgery: A Survey of Board-Certified Neurosurgeons in the United States and Updated Literature Review. World Neurosurgery, 2021, 150, e631-e638.	0.7	9
839	Elimination of fibrin ^ĵ a-chain cross-linking by FXIIIa increases pulmonary embolism arising from murine inferior vena cava thrombi. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, e2103226118.	3.3	10
840	Risk assessment and prevention of venous thromboembolism among hospitalized patients: Results of the regional multicenter study. Atherothrombosis, 2021, , 26-40.	0.1	Ο
841	Clinical and anamnestic characteristics and risk factors in patients with acute pulmonary embolism among residents of Kharkiv. Emergency Medicine, 2021, 17, 58-63.	0.0	2
842	Deep Venous Thrombosis and Risk of Consequent Sepsis Event: A Retrospective Nationwide Population-Based Cohort Study. International Journal of Environmental Research and Public Health, 2021, 18, 7879.	1.2	5

#	Article	IF	CITATIONS
843	Renal dysfunction in patients with pulmonary embolism: data from the SIRENA register. Russian Journal of Cardiology, 2021, 26, 4422.	0.4	7
844	Effect of introducing biologics to patients with rheumatoid arthritis on the risk of venous thromboembolism: a nationwide cohort study. Scientific Reports, 2021, 11, 17009.	1.6	5
846	Association between cardiovascular risk-factors and venous thromboembolism in a large longitudinal study of French women. Thrombosis Journal, 2021, 19, 58.	0.9	3
847	Thromboprophylaxis in critically ill patients: balancing on a tightrope. Minerva Anestesiologica, 2021, 87, 1239-1254.	0.6	3
848	Evaluating post-operative venous thromboembolism risk in urology patients using a validated risk assessment model. African Journal of Urology, 2021, 27, .	0.1	0
849	Retrospective cohort study of new-onset atrial fibrillation in acute pulmonary embolism on prognosis. BMJ Open, 2021, 11, e047658.	0.8	3
850	Acute Pulmonary Embolism: Its Diagnosis and Treatment From a Multidisciplinary Viewpoint. Deutsches Ärzteblatt International, 2021, , .	0.6	5
851	Non-invasive diagnosis of deep vein thrombosis from ultrasound imaging with machine learning. Npj Digital Medicine, 2021, 4, 137.	5.7	32
852	Venous thromboembolism: Recent advancement and future perspective. Journal of Cardiology, 2022, 79, 79-89.	0.8	19
853	iWRAP: A Theranostic Wearable Device With Real-Time Vital Monitoring and Auto-Adjustable Compression Level for Venous Thromboembolism. IEEE Transactions on Biomedical Engineering, 2021, 68, 2776-2786.	2.5	7
854	Acute Pulmonary Embolism. , 2022, , 700-722.		0
855	Diuretic vs. placebo in intermediate-risk acute pulmonary embolism: a randomized clinical trial. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 2-9.	0.4	13
856	Surgical and non-surgical approaches in the management of lower limb post-thrombotic syndrome. Expert Review of Cardiovascular Therapy, 2021, 19, 191-200.	0.6	3
858	Exhaled breath condensate in acute pulmonary embolism; a porcine study of effect of condensing temperature and feasibility of protein analysis by mass spectrometry. Journal of Breath Research, 2021, 15, 026005.	1.5	4
859	Patients for Thrombolysis. , 2015, , 107-130.		5
860	Upper extremity deep vein thrombosis treated with direct oral anticoagulants: a multi-center real world experience. Journal of Thrombosis and Thrombolysis, 2020, 50, 355-360.	1.0	16
861	Calf deep vein thrombosis – clinical relevance, diagnostic approaches and therapeutic options. Vasa - European Journal of Vascular Medicine, 2020, 49, 359-366.	0.6	6
862	The addition of echocardiographic parameters to PESI risk score improves mortality prediction in patients with acute pulmonary embolism: PESI-Echo score. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 250-257.	0.4	15

#	Article	IF	CITATIONS
863	Incidence and risk factors of deep vein thrombosis (DVT) after total hip or knee arthroplasty. Blood Coagulation and Fibrinolysis, 2017, 28, 126-133.	0.5	27
864	Psychotic, Mood, and Anxiety Disorders and Venous Thromboembolism: A Systematic Review and Meta-Analysis. Psychosomatic Medicine, 2020, 82, 838-849.	1.3	17
865	Virtual Monoenergetic Imaging and Iodine Perfusion Maps Improve Diagnostic Accuracy of Dual-Energy Computed Tomography Pulmonary Angiography With Suboptimal Contrast Attenuation. Investigative Radiology, 2017, 52, 659-665.	3.5	57
866	Venous thromboembolism prophylaxis in urology: A review. International Journal of Urology, 2017, 24, 589-593.	0.5	12
867	Safety of multidetector computed tomography pulmonary angiography to exclude pulmonary embolism in patients with a likely pretest clinical probability. Journal of Thrombosis and Haemostasis, 2017, 15, 1584-1590.	1.9	13
868	Risk of venous thromboembolism in immune-mediated inflammatory diseases: a UK matched cohort study. RMD Open, 2020, 6, e001392.	1.8	26
870	Lifting the fog in intermediate-risk (submassive) PE: full dose, low dose, or no thrombolysis?. F1000Research, 2019, 8, 330.	0.8	1
871	Advances in the diagnosis of acute pulmonary embolism. F1000Research, 2020, 9, 44.	0.8	16
872	Venous Thromboembolism Prophylaxis in Intensive Care Units (Review). Obshchaya Reanimatologiya, 2020, 16, 106-125.	0.2	2
874	Epidemiology of pulmonary embolism in today's context: analysis of incidence, mortality and problems of their study. Russian Journal of Cardiology, 2019, , 103-108.	0.4	15
875	Russian register of acute pulmonary embolism SIRENA: characteristics of patients and in-hospital treatment. Russian Journal of Cardiology, 2020, 25, 3849.	0.4	13
876	Acute ileofemoral venous thrombosis. Kardiologiya I Serdechno-Sosudistaya Khirurgiya, 2016, 9, 63.	0.1	5
878	ORAL ANTICOAGULANTS IN THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS: FOCUS ON APIXABAN. Meditsinskiy Sovet, 2017, , 56-62.	0.1	2
879	PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH CANCER. Atherothrombosis, 2019, , 8-24.	0.1	3
880	Interaction between Traditional Chinese Medicine and Anticoagulant/Antiplatelet Drugs. Current Drug Metabolism, 2019, 20, 701-713.	0.7	12
881	The Clots in Legs Or sTockings after Stroke (CLOTS) 3 trial: a randomised controlled trial to determine whether or not intermittent pneumatic compression reduces the risk of post-stroke deep vein thrombosis and to estimate its cost-effectiveness. Health Technology Assessment, 2015, 19, 1-90.	1.3	56
882	Different strategies for pharmacological thromboprophylaxis for lower-limb immobilisation after injury: systematic review and economic evaluation. Health Technology Assessment, 2019, 23, 1-190.	1.3	17
883	mHealth in Resource-Constrained Environments. , 2016, , 619-636.		1

#	Article	IF	CITATIONS
884	mHealth in Resource-Constrained Environments. International Journal of Sociotechnology and Knowledge Development, 2014, 6, 18-35.	0.4	2
885	Arrive: A retrospective registry of Indian patients with venous thromboembolism. Indian Journal of Critical Care Medicine, 2016, 20, 150-158.	0.3	28
886	Non-Vitamin K Antagonist Oral Anticoagulants: Redefining the Role of the Nurse to Improve Patient Care. Open Journal of Nursing, 2015, 05, 1142-1157.	0.2	1
887	Epidemiology, Clinical Presentations and In-Hospital Mortality of Venous Thromboembolism at the Douala General Hospital: A Cross-Sectional Study in Cameroon, Sub-Saharan Africa. World Journal of Cardiovascular Diseases, 2018, 08, 123-132.	0.0	8
888	Catheter-based therapies in acute pulmonary embolism. EuroIntervention, 2018, 13, 1721-1727.	1.4	15
889	Clinical Characteristics of Acute Pulmonary Embolism: An Analysis of 39 Cases. Advances in Clinical Medicine, 2021, 11, 4674-4680.	0.0	0
890	Thrombolytic Therapy in Pulmonary Thromboembolism. , 0, , .		0
891	How Do You Teach an Old Dog New Tricks? Lessons from Venous Thromboembolism Prophylaxis Guidelines. Southern Medical Journal, 2008, 101, 1195-1196.	0.3	0
892	Results of the ENDORSE Study in Hungary: Multinational, Cross-Sectional Study to Assess the Prevalence of Venous Thromboembolism Risk and Prophylaxis in Acute Hospital Care Setting. Hungarian Medical Journal, 2008, 2, 539-549.	0.0	0
893	Thromboprophylaxis After Major Orthopaedic Surgery: State of the Art. , 2009, , 29-38.		1
894	Fibrinolysis for Pulmonary Embolism. , 2010, , 351-361.		0
896	Thromboprophylaxis in Sports Injury. , 2011, , 127-134.		0
897	Diagnosis of acute pulmonary thromboembolism. , 2011, , 503-516.		0
899	The Immediate and Long-term Results of Endovascular Mechanical Fragmentation with Local Thrombolysis in the Groups of Patient at High and Intermediate-high Risk of Early Death Associated with Pulmonary Embolism. Flebologiya, 2015, 9, 27.	0.2	0
900	Russian Experience in Rational Thromboprophylaxis in Traumatology and Orthopaedics. N N Priorov Journal of Traumatology and Orthopedics, 2015, 22, 36-42.	0.1	0
901	Indirect Electroimpulse Myostimulation and Its Role in Treatment of Patients with Shin Bone Fractures. N N Priorov Journal of Traumatology and Orthopedics, 2015, 22, 21-25.	0.1	0
902	The Anticoagulation Treatment of Venous Thromboembolism: from Randomized Clinical Studies to the Data from the Real Clinical Practice. Flebologiya, 2016, 10, 106.	0.2	0
903	Thromboprophylaxis after Arthroplasty in Practice of Outpatient Trauma and Orthopedic Physician: is it necessary?. N N Priorov Journal of Traumatology and Orthopedics, 2016, 23, 32-39.	0.1	0

#	Article	IF	CITATIONS
905	Pulmoner Emboliye Güncel Yaklaşım. Arsiv Kaynak Tarama Dergisi, 2016, 25, 550-570.	0.1	0
906	Evaluating the efficiency of thrombodynamics test in the diagnosis of hemostatic system disorders in gynecologic surgical patients at high risk for venous thromboembolic events. Russian Bulletin of Obstetrician-Gynecologist, 2017, 17, 65.	0.0	3
907	The Management of the Patients with Deep Vein Thrombosis in Need of Emergency Surgical Intervention. Flebologiya, 2017, 11, 164.	0.2	1
908	International Perspectives on Safety, Quality, and Reliability of Surgical Care. , 2017, , 849-857.		0
909	Angiologie. , 2017, , 1-59.		0
910	EFFICIENCY OF PREOPERATIVE VENOUS THROMBOMOBOLISM PREVENTION IN ABDOMINAL SURGERY. Bulletin of Problems Biology and Medicine, 2018, 1.2, 205.	0.0	0
911	Cost-effectiveness of LMWHs versus UFH for the prevention of postsurgical venous thromboembolism at orthopedic department in Clinical Hospital Stip. Makedonsko Farmacevtski Bilten, 2018, 64, 79-88.	0.0	0
912	Optimal treatment of venous thromboembolism. MedicÃna Pro Praxi, 2018, 15, 26-29.	0.0	1
913	Clinical and Economic Outcomes of New Oral Anticoagulants in Orthopaedics. Serbian Journal of Experimental and Clinical Research, 2018, 19, 3-9.	0.2	0
914	Pulmoner Emboli Hastalarında Nötrofil/Lenfosit Oranı ve Trombosit/Lenfosit Oranı. Çağdaş Tıp Dergis , .	si, 0, 0.1	0
915	The Optimal Duration and Selection of Anti-coagulants after First Episode of Unprovoked Venous Thromboembolism. Clinical & Experimental Thrombosis and Hemostasis, 2018, 4, 1-6.	0.2	0
916	Prise en charge de l'embolie pulmonaire grave en réanimation. Medecine Intensive Reanimation, 2018, 27, 443-451.	0.1	2
917	Local low-dose urokinase thrombolysis for the management of haemodynamically stable pulmonary embolism with right ventricular dysfunction. EuroIntervention, 2018, 14, 238-246.	1.4	2
919	Factors in Pulmonary Embolus Diagnosis via CT Pulmonary Angiogram in Patients Undergoing Repair of Proximal Femur Fractures. The Open Orthopaedics Journal, 2018, 12, 236-251.	0.1	0
920	Kronik Derin Ven Trombozu Olan Hastada Akut Gelişen İliyak Ven Trombozunun Farmokomekanik Tedavisi: Olgu Sunumu. Bozok Tıp Dergisi, 0, , .	0.0	1
921	Stratification of deep vein thrombosis and pulmonary embolism risk factors after trauma and orthopedic surgery. Medical Herald of the South of Russia, 2018, 9, 17-28.	0.2	2
922	Incidence and Risk Factors of Recurrent Venous Thromboembolism after Pulmonary Embolism. Tuberculosis and Respiratory Diseases, 2019, 82, 341.	0.7	6
923	Pulmonary Artery. , 2019, , 529-533.e2.		0

#	Article	IF	CITATIONS
924	Therapeutic potential of apixaban at different stages of management of patients with pulmonary thromboembolism. Meditsinskiy Sovet, 2019, , 8-15.	0.1	0
925	Pulmonary embolism associated with Hodgkin lymphoma. Naucni Casopis Urgentne Medicine - Halo 194, 2019, 25, 110-115.	0.1	0
926	Outpatient treatment options for pulmonary embolism. Intervencni A Akutni Kardiologie, 2019, 18, 102-104.	0.0	0
928	(Rapidly progressive early onset dementia as the first symptom of paradoxical embolism). Cor Et Vasa, 2019, 61, 635-639.	0.1	0
929	Original, simplified, and modified pulmonary embolism severity indices in risk stratification of pulmonary embolism. Egyptian Journal of Bronchology, 2019, 13, 747-753.	0.3	0
930	Long-term outcomes of patients investigated for suspected upper extremities deep venous thrombosis irrespective of imaging results. Journal of the Royal College of Physicians of Edinburgh, The, 2020, 50, 19-24.	0.2	1
931	Prevention and treatment of venous thromboembolism in hospital and the community: a research programme including the ExACT RCT. Programme Grants for Applied Research, 2020, 8, 1-104.	0.4	1
932	CLINICAL AND ULTRASOUND CHARACTERISTICS IN TREATMENT GROUPS OF PATIENTS WITH ACUTE THROMBOSIS OF DEEP LOWER EXTREMITY. EurasianUnionofScientists, 2020, 6, 69-71.	0.0	0
933	Prevalence of thromboembolic (VTE) events in a South London District hospital: a retrospective study. Progress in Health Sciences, 2020, 10, 82-91.	0.1	0
934	Association between Sarcopenia/Lower Muscle Mass and Short-Term Regression of Deep Vein Thrombosis Using Direct Oral Anticoagulants. International Heart Journal, 2020, 61, 787-794.	0.5	4
935	Trombosis venosa profunda en extremidades inferiores: revisión de las técnicas de diagnóstico actuales y su simbiosis con el aprendizaje automático para un diagnóstico oportuno. Revista De Ciencias TecnolÓgicas, 2020, 3, 23-34.	0.0	1
936	Early Pulmonary Embolism Detection from Computed Tomography Pulmonary Angiography Using Convolutional Neural Networks. , 2020, , .		1
937	2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2021, 144, e368-e454.	1.6	319
938	2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain. Journal of the American College of Cardiology, 2021, 78, e187-e285.	1.2	336
939	Real-life impact of clinical prediction rules for venous thromboembolism in primary care: a cross-sectional cohort study. BMJ Open, 2020, 10, e039913.	0.8	3
940	Post-thrombotic Syndrome: Preventative and Risk Reduction Strategies Following Deep Vein Thrombosis. Vascular and Endovascular Review, 0, 3, .	0.2	2
941	Physical Activity as an Effect Modifier of the Association Between Obesity and Venous Thromboembolism: A Danish Population-Based Cohort Study. Clinical Epidemiology, 2020, Volume 12, 1361-1370.	1.5	2
942	CORRELATION OF D-DIMER LEVEL WITH THE PRESENCE AND SEVERITY OF PULMONARY EMBOLISM ON COMPUTED TOMOGRAPHY PULMONARY ANGIOGRAPHY. , 2020, , 33-34.		Ο

#	ARTICLE	IF	CITATIONS
943	Paradoxical embolism of the left brachial artery in a patient with deep vein thrombosis of the lower extremities, pulmonary embolism and patent foramen ovale. Kardiologiya I Serdechno-Sosudistaya Khirurgiya, 2020, 13, 270.	0.1	0
944	D-dimer: A role in ruling out pulmonary embolism in an emergency care department. Scripta Medica, 2020, 51, 28-33.	0.0	1
945	In-Hospital Outcome in Patients Underwent Extracorporeal Membrane Oxygenation in Life-Threatening High-Risk Pulmonary Embolism. International Journal of Heart Failure, 2020, 2, 187.	0.9	3
946	Acute Massive Pulmonary Embolism with Direct Visualization of a Free-floating Right Heart Thrombus Successfully Treated with Fibrinolysis: A Case Report. Prague Medical Report, 2020, 121, 42-48.	0.4	0
947	Vasculature obstruction level in pulmonary embolism and risk of pulmonary infarction. Pulmonologiya, 2020, 29, 673-678.	0.2	1
948	Implementation of clinical decision support system for anticoagulant prescribing for patients with deep vein thrombosis. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2020, 75, 69-76.	0.2	1
949	EcografÃa clÃnica en la enfermedad tromboembólica venosa. Revista Clinica Espanola, 2020, 220, 126-134.	0.2	1
950	VENÖZ TROMBOEMBOLİZMİN MALİYETLERİ VE EKONOMİK YÜKÜNÜN BELİRLENMESİNE İLÄ DERLEME: FARMAEKONOMİK ÖNLEYİCİ BİR TEDAVİ OLARAK DMAH. İşletme Bilimi Dergisi, 0, , 1-29.	°ÅžKİN S 0.2	sä°stematä
951	Impact of Preload on Right Ventricular Hemodynamics in Acute Pulmonary Embolism. Critical Care Medicine, 2020, 48, e1306-e1312.	0.4	5
952	Outpatient treatment of pulmonary embolism. Breathe, 2020, 16, 200069.	0.6	3
953	The importante of profilaxis in venous thromboembolism. Revista Ciencias Em Saude, 2020, 10, 1-3.	0.0	0
954	Analysis of Adherence to Thromboprophylaxis and Incidence of Venous Thromboembolism After Lower Limb Orthopaedic Surgery. Cureus, 2021, 13, e19746.	0.2	0
956	Anticoagulation Treatment in Venous Thromboembolism: Options and Optimal Duration. Current Pharmaceutical Design, 2022, 28, 296-305.	0.9	13
957	Pilot Trial of Neuromuscular Stimulation in Human Subjects with Chronic Venous Disease. Vascular Health and Risk Management, 2021, Volume 17, 771-778.	1.0	4
958	2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain. Journal of Cardiovascular Computed Tomography, 2022, 16, 54-122.	0.7	57
959	Plasma levels of plateletâ€derived microvesicles are associated with risk of future venous thromboembolism. Journal of Thrombosis and Haemostasis, 2022, 20, 899-908.	1.9	8
960	Risks of Testosterone Treatment. , 2022, , 1585-1590.		0
962	Chronic hypersensitivity pneumonitis is associated with an increased risk of venous thromboembolism: a retrospective cohort study. BMC Pulmonary Medicine, 2021, 21, 416.	0.8	5

#	Article	IF	CITATIONS
963	Association between obstructive sleep apnea and venous thromboembolism recurrence: results from a French cohort. Thrombosis Journal, 2022, 20, 1.	0.9	2
964	Risk of Unfavorable Outcomes of Thromboembolism with Antipsychotic Drug Use: Analysis Using the Japanese Adverse Drug Event Report Database. Japanese Journal of Clinical Pharmacology and Therapeutics, 2022, 53, 3-10.	0.1	0
965	Lipoprotein(a) and Pulmonary Embolism Severity-A Retrospective Data Analysis. Frontiers in Cardiovascular Medicine, 2022, 9, 808605.	1.1	3
966	FOCUS on sequelae of acute pulmonary embolism: does it pay off?. European Heart Journal, 2022, 43, 3399-3401.	1.0	2
968	Prognosis assessment model based on low serum calcium in patients with acute pulmonary thromboembolism. Respirology, 2022, , .	1.3	5
970	Current Knowledge on Factor V Leiden Mutation as a Risk Factor for Recurrent Venous Thromboembolism: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2022, 9, 883986.	1.1	7
971	(Acute pulmonary embolism). Cor Et Vasa, 2021, 63, 675-682.	0.1	0
972	State-of-Art in the Age Determination of Venous Thromboembolism: A Systematic Review. Diagnostics, 2021, 11, 2397.	1.3	8
973	Significance of pPTT-TAPSE and Mortality Prediction for Acute Pulmonary Thromboembolism in Emergency Department. Eurasian Journal of Emergency Medicine, 2022, 21, 56-61.	0.1	0
974	A Novel Electrocardiography Model for the Diagnosis of Acute Pulmonary Embolism. Frontiers in Cardiovascular Medicine, 2022, 9, 825561.	1.1	3
975	Endothelial Cell Phenotype, a Major Determinant of Venous Thrombo-Inflammation. Frontiers in Cardiovascular Medicine, 2022, 9, 864735.	1.1	17
976	Egg and cholesterol intake, apoE4 phenotype and risk of venous thromboembolism: findings from a prospective cohort study. British Journal of Nutrition, 2023, 129, 292-300.	1.2	3
977	Global impact of deep vein thrombosis awareness month: challenges and future recommendations. European Heart Journal, 2022, 43, 3379-3381.	1.0	12
978	Risk Stratification in Patients with Acute Pulmonary Embolism: Current Evidence and Perspectives. Journal of Clinical Medicine, 2022, 11, 2533.	1.0	12
979	MicroRNA 449a can Attenuate Protective Effect of Urokinase Against Pulmonary Embolism. Frontiers in Pharmacology, 2022, 13, 713848.	1.6	2
980	The changes of the calf-vein deformation and femoral vein peak velocity during ankle pump exercise with or without graduated compression stockings. BMC Musculoskeletal Disorders, 2022, 23, 435.	0.8	1
981	Venous Thromboembolism and Chronic Thromboembolic Pulmonary Hypertension: Novel Clinical Insights. Current Pharmaceutical Design, 2022, 28, 769-770.	0.9	1
000			€₽⁰₽2₽34₽

#	Article	IF	CITATIONS
983	Clinical experiences of high-risk pulmonary thromboembolism receiving extracorporeal membrane oxygenation in single institution. Tuberculosis and Respiratory Diseases, 0, , .	0.7	1
984	Role of CT and MRI in Cardiac Emergencies. Tomography, 2022, 8, 1386-1400.	0.8	3
985	Pulmonary Embolism and Comorbidity. Open Respiratory Archives, 2022, , .	0.0	0
986	Effectiveness and safety of extended treatment with direct oral anticoagulants for venous thromboembolism in Japan: A retrospective cohort study using claims data. Thrombosis Update, 2022, , 100113.	0.4	Ο
987	No evidence of a prospective relationship between serum zinc and venous thromboembolism in Caucasian men: a cohort study. BioMetals, 0, , .	1.8	0
988	Commentary on "Elevated plasma levels of plasminogen activator inhibitorâ€1 are associated with risk of future incident venous thromboembolism†A new role for plasminogen activator inhibitorâ€1—An inhibitor of fibrinolysis predicts future venous thromboembolic events and links them to obesity. Journal of Thrombosis and Haemostasis. 2022. 20. 1559-1561.	1.9	1
989	Comparative Analysis of All-Cause Health Care Resource Utilization and Costs Among Venous Thrombosis Patients Without Cancer Prescribed Apixaban or VKAs in France. Advances in Therapy, 2022, 39, 3766-3776.	1.3	1
990	Epidemiological study about the mental state of patients after a pulmonary embolism or deep venous thrombosis event. Blood Coagulation and Fibrinolysis, 2022, 33, 257-260.	0.5	2
991	Prevalence of Hemorrhagic Complications in Hospitalized Patients with Pulmonary Embolism. Journal of Personalized Medicine, 2022, 12, 1133.	1.1	1
992	Prognostic role of serial electrocardiographic changes in patients with acute pulmonary embolism. Data from the Italian Pulmonary Embolism Registry. Thrombosis Research, 2022, 217, 15-21.	0.8	7
994	Exogenous Urokinase Inhibits Proteasomal Degradation of Its Cognate Urokinase Plasminogen Activator Receptor. Frontiers in Pharmacology, 0, 13, .	1.6	1
995	Angiojet System Used in the Treatment of Submassive Pulmonary Embolism: A Case Report of Two Patients. Case Reports in Vascular Medicine, 2022, 2022, 1-6.	0.1	Ο
997	Recurrent thromboembolism, bleeding, and mortality in Asian patients with venous thromboembolism receiving different oral anticoagulants: A nationwide analysis. Medicine (United States), 2022, 101, e30412.	0.4	0
998	A Case of Pulmonary Embolism with Vomiting as the Only Initial Symptom and Literature Review. Advances in Clinical Medicine, 2022, 12, 8765-8769.	0.0	Ο
999	Blood pressure and risk of venous thromboembolism: a cohort analysis of 5.5 million UK adults and Mendelian randomization studies. Cardiovascular Research, 2023, 119, 835-842.	1.8	5
1000	PROGNOSTICATION BY RATIO OF TRICUSPID ANNULAR PLANE SYSTOLIC EXCURSION TO PULMONARY ARTERIAL SYSTOLIC PRESSURE BY ECHOCARDIOGRAPHY IN ACUTE PULMONARY EMBOLISM. , 2022, , 37-41.		Ο
1001	Intervention to Improve Compliance With National Guidelines on Venous Thromboembolism Chemoprophylaxis for Patients With Operatively Managed Ankle Fractures. Ochsner Journal, 2022, 22, 319-323.	0.5	1
1002	Feasibility of monitoring the resolution of acute pulmonary embolism with non-contrast-enhanced magnetic resonance imaging at one day, one week, one, three, and six months. Acta Radiologica, 0, , 028418512211224.	0.5	0

	CITATION REI	CITATION REPORT	
#	ARTICLE Identification of outcomes in clinical studies of interventions for venous thromboembolism in	IF	CITATIONS
1003	nonâ€pregnant adults. Journal of Thrombosis and Haemostasis, 2022, 20, 2204-2206. Immediate and delayed complications of inferior vena cava filters. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2023, 11, 587-594.e3.	0.9	0
1006	Rivaroxaban Treatment for Patients With Unprovoked or Provoked Venous Thromboembolism ― Subanalysis of the J'xactly Study ―. Circulation Reports, 2022, 4, 490-498.	0.4	0
1007	A PATIENT WITH CHEST PAIN AND ST-SEGMENT ELEVATION ON A RESTING ECG – A CASE STUDY. Emergency Medical Service, 2022, 9, 131-137.	0.1	0
1008	The Neutrophil-to-Lymphocyte Ratio's Predictive Utility in Acute Pulmonary Embolism: Systematic Review. Journal of Cardiovascular Emergencies, 2022, 8, 25-30.	0.1	10
1009	Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project. Life, 2022, 12, 1657.	1.1	1
1010	A Machine Learning Framework for Assessing the Risk of Venous Thromboembolism in Patients Undergoing Hip or Knee Replacement. Journal of Healthcare Informatics Research, 0, , .	5.3	0
1011	Epidemiology and prevention of venous thromboembolism. Nature Reviews Cardiology, 2023, 20, 248-262.	6.1	52
1013	Epidemiology and Treatment Patterns of Venous Thromboembolism: an Observational Study of Nationwide Time-Series Trends in Japan. Cardiology and Therapy, 2022, 11, 589-609.	1.1	2
1014	Venous thromboembolism: Why is it still a significant health problem?. Advances in Medical Sciences, 2023, 68, 10-20.	0.9	3
1015	Venous Thromboembolism at the National Healthcare Group, Singapore. Annals of the Academy of Medicine, Singapore, 2009, 38, 470-477.	0.2	40
1016	The relationship between pesi score and pulmonary venous flow parameters in patients with acute pulmonary embolism. Echocardiography, 2022, 39, 1532-1539.	0.3	1
1017	A deep learning approach for automated diagnosis of pulmonary embolism on computed tomographic pulmonary angiography. BMC Medical Imaging, 2022, 22, .	1.4	5
1018	Klinikai kockÃįzatbecslésen alapuló döntéshozatal a tüdÅ'emboliÃįs betegek kórhÃįzi elbocsÃįtÃįsa so Orvosi Hetilap, 2022, 163, 1152-1158.	rÃin. Ö.1	0
1019	B lymphocyte-deficiency in mice promotes venous thrombosis. Heliyon, 2022, 8, e11740.	1.4	3
1020	Comparing â€~clinical hunch' against clinical decision support systems (PERC rule, wells score, revised) Tj ETQ Medicine, 2022, 22, .	q1 1 0.78 0.8	4314 rgBT 4
1021	Pulmonary thromboembolism in adults: Experience from a tertiary care center. Medical Journal Armed Forces India, 2022, , .	0.3	0
1022	Immune-mediated inflammatory diseases and risk of venous thromboembolism: A Mendelian randomization study. Frontiers in Immunology, 0, 13, .	2.2	1

#	Article	IF	CITATIONS
1023	Today's view of hereditary thrombophilia. Vnitrni Lekarstvi, 2022, 68, 488-492.	0.1	0
1024	Pulmonary Embolism Risk Assessment Using Blood Copeptin Concentration and Pulmonary Arteries Thrombotic Burden Evaluated by Computer Tomography. Journal of Personalized Medicine, 2022, 12, 2084.	1.1	1
1025	Surgical treatment of pulmonary embolism in a 25-week pregnant woman. Acta Phlebologica, 2022, 23, .	0.1	0
1026	A new machine learning model for predicting severity prognosis in patients with pulmonary embolism: Study protocol from Wenzhou, China. Frontiers in Neuroinformatics, 0, 16, .	1.3	0
1027	Prolonged electrocardiography registration does not lead to increased diagnosis of atrial fibrillation in pulmonary embolism patients, but sex affects generic health-related quality of life: Findings from a randomized clinical trial. Medicine (United States), 2022, 101, e32197.	0.4	0
1028	<scp>Doseâ€dependent</scp> effects of red blood cell transfusion and case mix index on venous thromboembolic events in spine surgery. Vox Sanguinis, 2023, 118, 76-83.	0.7	3
1029	Chemical versus Mechanical and Chemical Venous Thromboembolism Prophylaxis in Neurocritically III Patients: A Cohort Study. Clinical Pharmacology: Advances and Applications, 0, Volume 15, 1-8.	0.8	0
1030	Examining the benefit of graduated compression stockings in the prevention of hospital-associated venous thromboembolism in low-risk surgical patients: a multicentre cluster randomised controlled trial (PETS trial). BMJ Open, 2023, 13, e069802.	0.8	0
1031	Modern approaches to the prevention of venous thromboembolic complications in patients with active cancer. Atherothrombosis, 2023, 12, 44-62.	0.1	0
1032	Genome-wide meta-analysis identifies 93 risk loci and enables risk prediction equivalent to monogenic forms of venous thromboembolism. Nature Genetics, 2023, 55, 399-409.	9.4	30
1033	Retrospective Analysis of the Safety and Efficacy of AngioJet Rheolytic ThrombectomyÂfor Acute Pulmonary Embolism: A Single-Center Study. Annals of Vascular Surgery, 2023, 92, 155-162.	0.4	1
1034	Serum C-reactive protein-to-albumin ratio may be a potential risk indicator for venous thromboembolism: Findings from a prospective cohort study. Nutrition, Metabolism and Cardiovascular Diseases, 2023, 33, 864-867.	1.1	1
1035	A retrospective review on importance and various preparation of low molecular weight heparin for cardio vascular diseases. International Journal of Pharmaceutical Chemistry and Analysis, 2023, 9, 188-195.	0.1	0
1036	Impact of Chronic Heart Failure on Acute Pulmonary Embolism in-Hospital Outcomes (From a) Tj ETQq1 1 0.7843	0.7 ⁹ BT /0	Overlock 10
1037	Effectiveness of systemic thrombolysis on clinical outcomes in high-risk pulmonary embolism patients with venoarterial extracorporeal membrane oxygenation: a nationwide inpatient database study. Journal of Intensive Care, 2023, 11, .	1.3	3
1038	Deep Vein Thrombosis After Earthquake: A Systematic Review and Meta-analysis. Disaster Medicine and Public Health Preparedness, 2023, 17, .	0.7	4
1039	Frontal QRS - T angle is associated with severity and prognosis of acute pulmonary embolism. Journal of Electrocardiology, 2023, 79, 8-12.	0.4	0
1040	Complement factors B, D, C3bBbP and risk of future venous thromboembolism. Clinical Immunology, 2023, 249, 109278.	1.4	Ο

#	Article	IF	CITATIONS
1041	Magnetic Particle Imaging in Vascular Imaging, Immunotherapy, Cell Tracking, and Noninvasive Diagnosis. Molecular Imaging, 2023, 2023, .	0.7	4
1042	Fecal pulmonary embolism: a case report and literature review. Forensic Science, Medicine, and Pathology, 0, , .	0.6	0
1043	Natural Language Processing in a Clinical Decision Support System for the Identification of Venous Thromboembolism: Algorithm Development and Validation. Journal of Medical Internet Research, 0, 25, e43153.	2.1	0
1044	Evaluation of systemic immune-inflammation index in acute deep vein thrombosis: A propensity-matched. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2023, 11, 972-977.e1.	0.9	4
1045	How to Combat Over-Testing for Patients Suspected of Pulmonary Embolism: A Narrative Review. Diagnostics, 2023, 13, 1326.	1.3	0
1046	Risk factors for hospital outcomes in pulmonary embolism: A retrospective cohort study. Frontiers in Medicine, 0, 10, .	1.2	2
1047	Progress in the treatment of acute pulmonary embolism and chronic thrombo-embolic pulmonary hypertension/disease. European Heart Journal Supplements, 2023, 25, B90-B94.	0.0	1
1048	Validity of Using Japanese Administrative Data to Identify Inpatients With Acute Pulmonary Embolism: Referencing the COMMAND VTE Registry. Journal of Epidemiology, 2024, 34, 155-163.	1.1	0
1051	Medizinische Rehabilitation bei Gefä̈́Yerkrankungen. Springer Reference Medizin, 2023, , 1-9.	0.0	0
1054	Interventional therapies for pulmonary embolism. Nature Reviews Cardiology, 2023, 20, 670-684.	6.1	15
1081	Rotational intravascular multi-direction ultrasound transducer for sonothrombolysis of retracted clots. , 2023, , .		0
1089	Improving VTE Identification through Adaptive NLP Model Selection and Clinical Expert Rule-based Classifier from Radiology Reports. , 2023, , .		0
1092	Kardiopulmonale Reanimation bei Erwachsenen. , 2024, , 134-145.		0
1094	Renal function-adapted D-dimer cutoffs in combination with a clinical prediction rule to exclude pulmonary embolism in patients presenting to the emergency department. Internal and Emergency Medicine, 0, , .	1.0	0